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SUMMARY
Thyroid hormones (THs) act in the brain to modulate
energybalance.Weshow that central triiodothyronine
(T3) regulates de novo lipogenesis in liver and lipid
oxidation in brown adipose tissue (BAT) through the
parasympathetic (PSNS) and sympathetic nervous
system (SNS), respectively. Central T3 promotes he-
patic lipogenesis with parallel stimulation of the ther-
mogenic program in BAT. The action of T3 depends
on AMP-activated protein kinase (AMPK)-induced
regulation of two signaling pathways in the ventrome-
dial nucleus of the hypothalamus (VMH): decreased
ceramide-inducedendoplasmic reticulum (ER) stress,
which promotes BAT thermogenesis, and increased
c-Jun N-terminal kinase (JNK) activation, which con-
trols hepatic lipid metabolism. Of note, ablation of
AMPKa1 in steroidogenic factor 1 (SF1) neurons of
the VMH fully recapitulated the effect of central T3,
pointing to this population in mediating the effect of
central THsonmetabolism.Overall, these findings un-
cover the underlying pathways through which central
T3 modulates peripheral metabolism.
INTRODUCTION
The thyroid axis plays amajor role in the regulation of energy bal-
ance and metabolism (Fliers et al., 2010; Warner and Mittag,
2012; Lo´pez et al., 2013; Mullur et al., 2014). One of the main
features of patients with thyroid dysfunction is the concurrence
of hyperphagia and weight loss in hyperthyroidism (Silva, 2006;
Lo´pez et al., 2013; Mullur et al., 2014). These beneficial effects
have led to the development of selective thyroid hormone (TH)
mimetics (Finan et al., 2016) as powerful new tools against
atherosclerosis and obesity.
The classical view assumes that most physiological effects of
THs (triiodothyronine [T3] and its prohormone, thyroxine [T4]) are
exerted at the peripheral level (Silva, 2006; Sinha et al., 2012).
However, recent evidence indicates that TH actions on energy
metabolism are centrally mediated (Fliers et al., 2010; Warner
and Mittag, 2012; Lo´pez et al., 2013; Mullur et al., 2014). THs
modulate food intake through their action in the arcuate nucleus
of the hypothalamus (ARC) (Coppola et al., 2007; Vella et al.,
2011; Varela et al., 2012). THs also modulate energy expenditure
(EE). This effect has been conventionally ascribed to their direct
action on peripheral tissues, such as brown adipose tissue
(BAT) and skeletal muscle (Silva, 2006; Cannon and Nedergaard,
2010), but recent evidence has challenged that view. Indeed, T3
acts in the ventromedial nucleus of the hypothalamus (VMH) to
regulate thermogenesis in BAT (Lo´pez et al., 2010) and browning
of white adipose tissue (WAT) (Martı´nez-Sa´nchez et al., 2017).
The central effect of THs has also been implicated in the regula-
tion of endogenous glucose production and insulin sensitivity
(Fliers et al., 2010). Of note, selective interference with the
transmission of the sympathetic and parasympathetic nervous
system (SNS and PSNS) completely abolishes the effect of
central T3 on glucose homeostasis (Fliers et al., 2010). However,
it is totally unknown whether central actions of THs regulate
peripheral lipid metabolism. The aims of this study were (1) to
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determine whether central THs regulate peripheral lipid meta-
bolism, (2) to characterize the molecular mechanisms leading
to that effect, and (3) to investigate whether those actions were
part of a coordinated response integrating lipid homeostasis
and energy balance at the whole-body level.
RESULTS
Hyperthyroidism Is Associated with Tissue-Specific
Regulation of the Lipogenesis Pathway
T4-treated rats showed decreased body weight despite hyper-
phagia and increased circulating levels of T4 and T3 (Figure S1A).
In the liver (but not muscle, WAT, or BAT), the global effect of
hyperthyroidism promoted de novo lipogenesis, as indicated
by the decreased phosphorylated AMP-activated protein kinase
(pAMPK) and acetyl-CoA carboxylase (pACC) and increased
fatty acid synthase (FAS), as well as increased hepatic Oil Red
O staining and triglyceride (TG) levels (Figures S1B–S1D).
Central T3 Regulation of Lipid Metabolism in Liver
and BAT
Chronic ICV (intracerebroventricular) T3 induced weight loss
and a slight decrease in thyrotropin-releasing hormone (TRH,
codified by Trh) mRNA in the paraventricular nucleus of the
hypothalamus (PVH), but altered neither feeding nor circulating
thyroid-stimulating hormone (TSH), nor T4 and T3 levels (Fig-
ure S1E). The weight-reducing effect of central T3 was recapitu-
lated in hypothyroid rats (data not shown). ICV administration of
T3 promoted a comparable pattern of protein expression in pe-
ripheral tissues to that observed in hyperthyroid rats (Figure 1A).
Accordingly, central administration of T3 increased hepatic lipid
and TG content (Figures 1B and 1C), de novo TG synthesis (Fig-
ure 1D), as well as the hepatic activity and/or mRNA expression
of phosphatidate phosphatase 1 (LIPIN1, codified by Lpin1) and
diacylglycerol O-acyl-transferase 1 (DGAT1, codified by Dgat1),
enzymes catalyzing the formation of diglyceride (DAG) and TG,
respectively (FigureS1F).Ofnote, nochangeswere found ineither
lipid oxidative gene expression, such as the liver isoform of carni-
tine palmitoyltransferase 1a (CPT1a, codified by Cpt1a), nuclear
respiratory factor 1 (NFR1, codified by Nrf1), and peroxisome-
proliferator-activated receptor-gamma co-activator 1 alpha and
beta (PGC1a and b, codified byPpargc1a andPpargc1b, respec-
tively) (Figure S1G); liver lipid oxidation rate andmitochondrial ox-
ygen consumption in vivo and in vitro (Figure S1H); or serum ke-
tone bodies (Figure S1I).
Analysis of BAT after central T3 infusion revealed increased
mRNA expression of thermogenic markers, such as uncoupling
protein 1 and 3 (UCP1 and 3, codified by Ucp1 and Ucp3,
respectively), PGC1a, and fibroblast growth factor 21 (FGF21,
codified by Fgf21), as well as protein levels of UCP1 (Figures
1E and 1F). The effect of central T3 on BAT UCP1 expression
was recapitulated in hypothyroid rats (data not shown). Notably,
the effect of T3 on FGF21 was specific for BAT because no
changes were found in either its hepatic mRNA expression
(vehicle ICV, 100% ± 37.0%; T3 ICV, 74.13% ± 22.4%) or circu-
lating levels (vehicle ICV, 93.54 ± 1.98 U/mL; T3 ICV, 93.04 ±
1.44 U/mL). Central T3 induced a marked activation of brown
fat, as indicated by a higher 2-18F-fluoro-2-deoxy-2-glucose
(18F-FDG) uptake analyzed by positron emission tomography-
computed tomography (PET-CT) (Figure 1G), associated with
increased lipid oxidation and mitochondrial oxygen consump-
tion (Figure 1H). Electron microscopy analysis of BAT showed
decreased mitochondrial density and lipid droplet (LD) content,
whereas the size of the mitochondria was increased (Figure 1I),
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Figure 1. Effect of Central THs on Liver and BAT
(A) Protein levels of the AMPK pathway in the liver, WAT, muscle, and BAT (n = 8–17 rats/group).
(B and C) Oil Red O (203; scale bar, 100 mm) staining analysis (B) and TG levels in the liver (n = 8–9 rats/group) (C).
(D) [3H]-acetate incorporation into TGs in the liver (n = 6–7 rats/group).
(legend continued on next page)
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which is indicative of activation of BAT (Thomsom et al., 1969). A
slight, but not significant, decrease in BAT lipogenesis rate was
found after T3 ICV treatment with no variations in TG and fatty
acid (FA) concentration (Figure S1J). After central administration
of T3, rats showed increased EE and decreased respiratory quo-
tient (RQ, indicating increased lipid utilization), consistently with
enhanced BAT-dependent oxidation fueled mainly by FA (Fig-
ure 1J), as well as reduced locomotor activity (LA) (Figure 1J).
Overall, our results indicate that the effect of central T3 on liver
and BAT is mediated via a direct action of THs in the central ner-
vous system (CNS). This was further substantiated by the
absence of changes in liver and BAT AMPK pathway following
intraperitoneal (i.p.) administration of T3 at the same dose used
in the ICV injections (Figure S1K).
The Autonomic Nervous System Mediates Central T3
Actions on Lipid Metabolism in Liver and BAT
We examined the contribution of the autonomic nervous sys-
tem (ANS) in mediating the regulation of liver and BAT lipid
metabolism following central administration of T3. Previous
evidence demonstrated that T3 ICV increases c-FOS expression
in the raphe pallidus (RPa) and the inferior olive (IO) nuclei
(Lo´pez et al., 2010). Our data showed that central T3 administra-
tion induced c-FOS expression in the dorsal nucleus of the vagus
(DMV) (Figure 1K; normalized data, vehicle ICV, 100% ± 20.6%;
T3 ICV, 812.75% ± 101.90%, p < 0.001). Therefore, we sought
to determine whether the effect of central T3 on hepatic lipid
metabolism involved vagal innervation. Thus, we compared the
effect of T3 in vagotomized (VGX) and sham rats. ICV T3 admin-
istration decreased body weight (but not food intake) in sham
and VGX rats (Figure S1L). However, vagotomy was sufficient
to blunt T3-mediated induction of hepatic AMPK pathway (Fig-
ure 1L), as well as the mRNA expression of LIPIN1 and DGAT1
(Figure S1L) and liver FA content (data not shown). These find-
ings indicate that the vagus nerve mediates the effects of central
T3 on liver lipid metabolism.
T3 ICV increased BAT sympathetic nerve traffic (Figure 1M).
Pharmacological inactivation of b3 adrenoceptors (b3-ARs)
by subcutaneous administration of the specific antagonist
SR59230A (Lo´pez et al., 2010; Martı´nez de Morentin et al.,
2014) prevented the effect on body weight associated with
central administration of T3 without interfering with the feeding
response (body weight change: vehicle ICV vehicle subcutane-
ously [s.c.], 19.57 ± 2.88 g; T3 ICV vehicle s.c., 10.25 ± 1.91 g,
p < 0.01 versus vehicle ICV vehicle s.c.; T3 ICV SR59230A s.c.,
16.75 ± 2.34 g, p < 0.05 versus T3 ICV vehicle s.c.; food intake:
vehicle ICV vehicle s.c., 29.18 ± 1.09 g; T3 ICV vehicle s.c.,
27.34 ± 0.94 g; T3 ICV SR59230A s.c., 30.50 ± 0.70 g). Further-
more, SR59230A blocked the T3-mediated activation of the
AMPK pathway in BAT (Figure 1N). No changes were detected
in T3-induced lipogenesis pathway in liver (Figure S1M). Overall,
these data indicate that T3 acts in the CNS to regulate thermo-
genesis and AMPK signaling in BAT (but not in liver) via increased
SNS activation of the b3-AR.
Central T3 Regulates Lipid Uptake in BAT
To determine how central T3-mediated increase in hepatic lipo-
genesis impacts FA uptake in peripheral tissues, T3 was ICV
injected to rats pre-treated with 14C-oleate. Analysis of serum
revealed a more rapid accumulation of 14C in the T3-treated
rats (Figure 2A), with a shift toward the radiolabel being more
abundant in the aqueous rather than in the lipid phase (Figure 2B).
This suggested that FA removal from serum was increased
alongside elevated b-oxidation of lipids, driving labeled water-
soluble metabolites into the circulation. Central T3 increased
14C uptake in both liver and BAT per gram of tissue, where
BAT exhibited the highest uptake rate (Figure 2C). However,
when correcting for total organ weight, the liver had a signifi-
cantly larger contribution to total lipid clearance (Figure 2D). Of
note, liver displayed a significant increase in 14C-labeled TGs,
indicating that FAs were being incorporated into newly synthe-
sized TGs (Figure 2E), in keeping with the expression data of
AMPK pathway, hepatic lipid, TG content, and lipogenesis (Fig-
ures 1A–1D), as well as LIPIN1 and DGAT1 (Figure S1F). In
contrast, the tendency of reduced lipogenesis in BAT (Fig-
ure S1J), together with increased oxidative/thermogenic gene
expression and elevated EE, glucose uptake, and mitochondrial
and lipid droplet changes (Figures 1E–1J), suggests that the
lipids being taken up by BAT serve as fuel for thermogenesis.
Comparably, no regulation of 14C uptake was detected in WAT
after central T3 administration in 14C-oleate-infused rats (Figures
2C and 2D), indicating that this treatment had a net EE rather
than energy storage effect.
T3 in the VMH Regulates Lipid Metabolism in Liver
and BAT
Next,weperformedadministrationof T3 into theVMHor theARC.
The correct position of the cannulae was verified by histological
(E) mRNA levels of BAT genes (n = 5–7 rats/group).
(F) Protein levels of UCP1 in the BAT (n = 14 rats/group).
(G) 18F-FDG uptake analysis (n = 8 rats/group).
(H) Lipid oxidation rate, oxygen consumption rate in the BAT, and oxygen consumption in BAT mitochondria (n = 6–7 rats/group).
(I) Electronmicroscopy images (4,0003; scale bar, 10 mm) and quantification of lipid droplet (LD) andmitochondria number/area unit, size, and ultrastructure in the
BAT (n = 4 rats/experimental group, 30 images/animal).
(J) Cumulative EE, RQ, and LA (n = 5 rats/group).
(K) c-FOS images (103; scale bar, 50 mm) and staining analysis in the dorsal nucleus of the vagus (DMV) (n = 4 rats/group, 9–32 sections/animal) of rats ICV treated
with vehicle or T3.
(L) Protein levels of the AMPK pathway in the liver of sham or VGX rats ICV treated with vehicle or T3 (n = 11–14 rats/group).
(M) Sympathetic nerve activity (SNA) in the BAT (n = 8–11 rats/group) of rats ICV treated with vehicle or T3.
(N) Protein levels of the AMPK pathway in the BAT of rats ICV treated with vehicle or T3 and s.c. treated with SR59230A (n = 7 rats/group).
*p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle ICV. #p < 0.05 T3 ICV vehicle s.c. versus T3 ICV SR59230A s.c. Data are expressed asmean ± SEM. The bands in
gels from (A), (F), (L), and (N) have been spliced from the same original gels. CC, central canal; HN, hypoglossal nucleus; ND, non-detected; SUV, standardized
uptake value. See also Figure S1.
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examination (Figures S2A and S2B). In addition, when compared
with acute injections in the VMH, chronic cannulae did not in-
crease the immunoreactivity or the protein levels of inflammation
markers in the VMH, such as ionized calcium-binding adaptor
molecule 1 (IBA1), interleukin 6 (IL-6), nuclear factor kappa-
light-chain enhancer of activated B cells (NFkB), and phosphory-
lated IkB kinase (pIKK) (Figures S2C and S2D).
T3 in the VMH promoted a feeding-independent weight loss
and reduced adiposity (Figure 2F), associated with increased
UCP1 protein levels in BAT (Figure 2G). This response wasmain-
tained when T3 was given for longer periods of time (Figure S2E),
indicating that this action likely contributes to hyperthyroidism-
induced weight loss. We found that VMH T3 increased pAMPK
and pACC in BAT (Figure 2H). Conversely, it induced a downre-
gulation of the AMPK pathway in the liver (Figure 2I), alongside
increased lipid and TG accretion (Figures 2J and 2K), resembling
the effects observed after ICV T3. To control the specificity, we
analyzed ‘‘missed’’ T3 injections in ‘‘VMH neighboring’’ areas,
without affecting the VMH; no changes in the AMPK pathway
in liver and BAT were detected (Figure S2F). When T3 was
administered into the ARC, there was a tendency for increased
body weight at the end of the treatment, associated with hyper-
phagia, but no alterations in body composition (Figure S2G) or
UCP1 protein levels in BAT (Figure S2H). Notably, no effects
were found either in liver or BAT lipogenic program (Figure S2I).
To test this further, we ablated TH receptor (TR) action in the
VMH of euthyroid and hyperthyroid rats by delivery of adenovi-
ruses encoding a dominant-negative mutant of TR (TR-DN) or
GFP (Lo´pez et al., 2010). The infection efficiency was demon-
strated by assayingGFP in the VMH (similar to Figure S3A). Injec-
tion of TR-DN into the VMH of euthyroid rats exerted opposite
effects on liver and BAT AMPK pathway compared to those
evoked by T3 administration in this same nucleus (Figure S2J).
Of note, when adenoviruses harboring TR-DN targeted the
VMH of hyperthyroid rats, they induced feeding-independent
weight gain (body weight change: hyperthyroid GFP, 8.23 ±
2.0 g; hyperthyroid TR-DN, 15.0 ± 1.51 g, p < 0.01; food intake:
hyperthyroid GFP, 31.35 ± 1.63 g; hyperthyroid TR-DN, 31.4 ±
1.44 g) and blunted the effect of hyperthyroidism on BAT meta-
bolism (Figures 2L and 2M), but increased liver AMPK signaling
(Figure 2N) and subsequently reduced hepatic lipid (Figure 2O)
and TG content (Figure 2P). Next, we examined the effect of
vagotomy on the actions of VMH T3 on liver and BAT. Our results
were consistent with those obtained with ICV T3 injection, as
vagotomy totally reverted the effects of VMH T3 on hepatic
AMPK pathway (Figure 2Q), lipid content (Figure 2R), and TG
levels (Figure 2S), without impacting either body weight (Figures
S2K and S2L) or UCP1 (Figure S2M) in BAT. Altogether, these
data demonstrate that the effect of T3 on the PSNS and liver
metabolism originates from the TRs in the VMH.
Central Effects of T3 on Liver and BAT Depend on AMPK
in the VMH
Hypothalamic AMPK mediates the central effect of T3 on BAT
thermogenesis (Lo´pez et al., 2010). To elucidate the contribution
of AMPK activity in the hypothalamus to the lipogenic program in
liver and BAT, adenoviruses encoding either a dominant-nega-
tive isoform of AMPKa (AMPKa-DN) (Lo´pez et al., 2010; Martı´nez
de Morentin et al., 2014) or GFP were injected into the VMH
of euthyroid rats. The infection efficiency was demonstrated by
assaying hypothalamic expression of GFP into the VMH (Fig-
ure S3A). Treatment with AMPKa-DN adenoviruses induced a
feeding-independent weight loss (Figure 3A) associated with
increased UCP1 levels in BAT (Figure 3B). Of note, inhibition
of AMPKa recapitulated the effects of T3 injection in the
VMH, namely increased AMPK signaling in BAT (Figure 3C) and
decreased AMPK signaling and elevated lipid and TG content
in the liver (Figures 3D–3F). Thus, we hypothesized that the cen-
tral effect of T3 on hepatic andBATmetabolismwasmediated by
specific inhibition of AMPK in the VMH. To test this, adenoviruses
encoding either a constitutively active isoform of AMPKa
(AMPKa-CA) (Lo´pez et al., 2010; Martı´nez de Morentin et al.,
2014) or GFP were injected into the VMH of hyperthyroid rats.
Overexpression of AMPKa-CA in the VMH was accompanied
by weight gain in hyperthyroid rats, but not in euthyroid rats,
with no alteration in feeding (Figure S3B). These effects were
associated with reversal of the hyperthyroidism-induced effect
on the lipogenic de novo pathway in liver and BAT (Figures 3G
and 3H). To test this, AMPKa-CA adenoviruses were adminis-
tered into the VMH of rats centrally treated with T3. Our data
showed that constitutive activation of AMPK in the VMH reversed
the effect of central T3 on body weight in a feeding-independent
manner (Figure S3C) and normalized UCP1 levels in BAT
(Figure S3D). Moreover, AMPKa-CA in the VMH reversed the ef-
fects of central T3 on the AMPK pathway in liver and BAT (Fig-
ures 3I and 3J). Together, these results are consistent with the
Figure 2. Effect of T3 within the VMH on Liver and BAT
(A and B) 14C levels in serum (A) and lipid or aqueous phases (B) of rats ICV treated with vehicle or T3 (n = 9 rats/group).
(C–E) Total 14C content (C); 14C content corrected by tissue/organ weight in the liver, BAT, andWAT (D); and 14C TG content in serum, liver, and BAT (E) of rats ICV
treated with vehicle or T3 (n = 9 rats/group).
(F) Body weight change, food intake, and body mass change of rats treated in the VMH with vehicle or T3 (n = 16–17 rats/group; 7 rats/group for NMR analysis).
(G–I) Protein levels of UPC1 in the BAT and the AMPK pathway in the BAT and liver of rats treated in the VMH with vehicle or T3 (n = 14 rats/group).
(J and K) Oil Red O (203; scale bar, 100 mm) staining analysis (J) and TG levels in the liver of rats treated in the VMH with vehicle or T3 (n = 8–9 rats/group) (K).
(L–N) Protein levels of the AMPKpathway in the BAT (L) and liver (M) andUCP1 in the BAT (N) of rats treated in the VMHwith adenoviruses encodingGFP or TR-DN
(n = 8 rats/group).
(O and P) Oil Red O (203; scale bar, 100 mm) staining analysis (O) and TG levels in the liver of rats treated in the VMH with adenoviruses encoding GFP or TR-DN
(n = 8 rats/group) (P).
(Q) Protein levels of the AMPK pathway in the liver of sham or VGX rats treated in the VMH with vehicle or T3 (n = 8 rats/group).
(R and S) Oil Red O (203; scale bar, 100 mm) staining analysis (R) and TG levels in the liver of sham or VGX rats treated in the VMH with vehicle or T3
(n = 8 rats/group) (S).
*p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle ICV, vehicle VMH, sham, or GFP. Data are expressed as mean ± SEM. The bands in gels from (H), (I), (L)–(N), and
(Q) have been spliced from the same original gels. See also Figure S2.
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observation that a reduction of AMPK activity in the VMH medi-
ates the central effects of THs on liver and BAT lipid metabolism.
Ablation of AMPKa1 in SF1 Neurons of the VMH Fully
Recapitulates the Effect of Central T3 on BAT and Liver
Metabolism
It is known that steroidogenic factor 1 (SF1) neurons in the
VMHplay amajor role in the regulation of energy balance by inte-
grating peripheral signals (such as leptin, insulin, and estradiol)
(Dhillon et al., 2006; Xu et al., 2011b; Chiappini et al., 2014)
and central mediators (such as glutamate) (Tong et al., 2007).
Moreover, it has been reported that SF1 neurons project to
autonomic centers modulating the SNS (Lindberg et al., 2013;
Chiappini et al., 2014). Given that T3 selectively regulates hypo-
thalamic AMPKa1 (but not AMPKa2) expression and activity
(Lo´pez et al., 2010), we generated an SF1 neuron-specific
AMPKa1 mouse line (SF1-Cre AMPKa1flox/flox) by crossing
floxed AMPKa1 mice (Nakada et al., 2010) and SF1-Cre mice,
which express Cre recombinase under SF1 promoter, hence
targeting subsets of neurons of the VMH (Dhillon et al., 2006).
Allele-specific PCR demonstrated that we successfully deleted
AMPKa1 in the SF1 population of the VMH (Figure S4A). Dele-
tion of AMPKa1 was observed in tissues in which SF1 is also
endogenously expressed, such as the adrenal gland, testis,
Figure 3. Effect of Activation of AMPK within the VMH on the Central Actions of THs on Liver and BAT
(A) Body weight change and food intake of rats treated in the VMH with adenoviruses encoding GFP or AMPKa-DN (n = 23–25 rats/group).
(B–D) Protein levels of UCP1 in the BAT (B) and the AMPK pathway in the BAT (C) and liver (D) of rats treated in the VMH with adenoviruses encoding GFP
or AMPKa-DN (n = 12–13 rats/group).
(E and F) Oil Red O (203; scale bar, 100 mm) staining analysis (E) and TG levels in the liver of rats treated in the VMH with adenoviruses encoding GFP or
AMPKa-DN (n = 12–14 rats/group) (F).
(G andH) Protein levels of the AMPK pathway in the liver (G) and BAT (H) of euthyroid and hyperthyroid rats treated in the VMHwith adenoviruses encodingGFP or
AMPKa-CA (n = 7 rats/group).
(I and J) Protein levels of the AMPK pathway in the liver (I) and BAT (J) of rats ICV treated with vehicle or T3 and treated in the VMH with adenoviruses encoding
GFP or AMPKa-CA (n = 7 rats/group).
*p < 0.05, **p < 0.01, ***p < 0.001 versus GFP, euthyroid GFP, and vehicle ICV GFP; #p < 0.05, ##p < 0.01, ###p < 0.001, hyperthyroid GFP versus hyperthyroid
AMPKa-CA or T3 ICV GFP versus T3 ICV AMPKa-CA. Data are expressed as mean ± SEM. The bands in gels from (B)–(D) and (G)–(J) have been spliced from the
same original gels. See also Figure S3.
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and pituitary (Figure S4A). In contrast, other tissues examined,
including the cerebellum, cerebral cortex, and liver, did not
show Cre-mediated recombination (Figure S4A). In addition,
we also measured AMPKa1 levels using qRT-PCR and found
significantly decreased expression of AMPKa1 in the VMH, but
not in the cerebral cortex (Figure S4B) or liver (data not shown).
To further verify AMPKa1 deletion in the SF1 population of the
VMH, we performed in situ hybridization using an oligo-labeled
probe against the deleted sequence. AMPKa1 mRNA (codified
by Prkaa1) was reduced specifically in the VMH of SF1-Cre
AMPKa1flox/flox mice, confirming the specific AMPKa1 deletion
in SF1 neurons of the VMH (Figure S4C). Western blot analysis
of the AMPK pathway in the VMH showed decreased pAMPK,
AMPKa1 (but not AMPKa2), and pACC protein content (Fig-
ure S4D). On the other hand, FAS expression was elevated in
the VMH of SF1-Cre AMPKa1flox/flox mice (Figure S4D).
SF1-Cre AMPKa1flox/flox mice showed a feeding-independent
decrease in body weight and adiposity (Figures 4A–4C), coupled
with increased EE (Figure 4D) and activation of the brown fat, as
demonstrated by a higher 18F-FDG uptake analyzed by PET-CT
(Figure 4E), BAT temperature (Figure 4F), and BAT sympathetic
nerve traffic (Figure 4G). Of note, pharmacological inactivation
of b3-AR with SR59230A reverted (in a feeding-independent
manner) the weight loss and increased BAT temperature of
SF1-Cre AMPKa1flox/flox mice (Figures S4E–S4G). Molecular
analysis of BAT showed elevated mRNA and/or protein expres-
sion of all the thermogenic markers examined (Figures 4H and
4I). In relation to the liver, SF1-Cre AMPKa1flox/flox mice showed
decreased activation of the AMPK pathway (Figure 4J), which
was indicative of increased lipogenesis, as demonstrated by
augmented hepatic TG content (Figure 4K). Overall, this evi-
dence indicated that deletion of AMPKa1 in SF1 neurons of the
VMH fully recapitulated the central effect of THs on BAT and liver
metabolism.
THs Alter Hypothalamic Lipid Composition and Reduce
Ceramide Levels
To assess the molecular mechanisms mediating the effects
of TH-induced decrease in AMPK in the VMH, we performed
several experiments. Given that AMPK is one of the main up-
stream regulators of lipid metabolism (Kahn et al., 2005; Lo´pez
et al., 2016), we assayed hypothalamic lipid composition. We
found no alterations in any of the saturated and unsaturated
FAs measured in either the hypothalamus or cortex of hyper-
thyroid rats when compared with euthyroid rats (Figure S5A).
Comparative multivariate analysis of the data identified clear
differences in complex lipid profiles in the hypothalamus (Fig-
ure S5B), but not in the cortex (data not shown), between the
two experimental groups. Thus, hyperthyroid rats displayed
accumulation of most of the lipids analyzed except for ceram-
ides, which were reduced in the hypothalamus and increased
in the cortex (Figure S5C). Further analysis of individual ceram-
ides showed that all species analyzed were decreased (Cer18,
Cer20, and Cer24) or trended toward a decrease (Cer22) in
the hypothalamus of hyperthyroid rats (Figure 5A). Consistent
with this, we detected major changes in the mRNA expression
profiles of key enzymes involved in the metabolism of complex
lipids in the hypothalamus (Figure 5B), but not in the cortex (Fig-
ure S5D), of hyperthyroid rats. Notably, the enzymes involved in
ceramide metabolism were also affected by the hyperthyroid
status in the hypothalamus, showing reduced expression of
ceramide synthase (LASS1, also called CERS1, codified by
Lass1, also called Cers1) and elevated expression of sphingo-
myelin synthase 1 (SGMS1, codified by Sgms1) (Figure 5B),
which is consistent with the decreased ceramide concentration.
Conversely, in the cortex of hyperthyroid rats there was signifi-
cant upregulation of LASS1 (Figure S5D), which agrees with
the augmented ceramide levels.
THs Reduce Hypothalamic ER Stress
Current evidence has demonstrated that central ceramide-
induced lipotoxicity triggers endoplasmic reticulum (ER) stress,
leading to weight gain and decreased sympathetic tone and
BAT thermogenesis (Contreras et al., 2014). Thus, we specu-
lated that the reduced hypothalamic ceramide concentration
induced by THs might impact ER stress and the protein levels
of the unfolded protein response (UPR). Our data showed that
hyperthyroid rats have reduced protein levels of UPR markers
in the hypothalamus, such as activating transcription factor 6
alpha (ATF6a), C/EBP homologous protein (CHOP), and phos-
phorylated PKR-like ER kinase (pPERK). Moreover, the protein
levels of the chaperone GRP78 (glucose-regulated protein 78
KDa, which acts upstream of the UPR to modulate protein
folding in reply to cellular insults that lead to ER stress) were
increased in the hypothalamus of hyperthyroid rats (Figure 5C).
Similarly, ICV administration of T3 promoted decreased levels
of the entire UPR, together with increased GRP78, in the medio-
basal hypothalamus (MBH) (Figure 5D). These responses were
recapitulated when T3 was administered in the VMH (Figure 5E),
which also decreased VMH ceramide concentration (Figure 5F).
Overall, this evidence demonstrates that THs reduce hypotha-
lamic ceramide content and ER stress. In contrast, according
to the elevated ceramide levels, the UPR was upregulated in
the cortex, which was indicative of induced ER stress (Fig-
ure S5E). Next, we analyzed the UPR and the ceramide levels
in the VMH of rats treated with adenoviruses harboring
AMPKa-DN in that nucleus. We observed decreased ER stress
(Figure 5G) and a tendency for a decrease in the VMH ceramide
concentration (Figure 5H). Based on these observations, we hy-
pothesized that the central effect of T3 on ER stress is mediated
by specific inhibition of AMPK in the VMH. To address this pos-
sibility, adenoviruses encoding AMPKa-CA were injected into
the VMH of hyperthyroid rats. Overexpression of AMPKa-CA
reversed the hyperthyroid-induced downregulation of hypo-
thalamic ER stress (Figure 5I). In keeping with this evidence,
SF1-Cre AMPKa1flox/flox mice showed decreased ER stress in
the VMH (Figure 5J).
Ceramides and Induction of ER Stress Reverse the
Effect of Central THs on BAT, but Not on Liver
To address whether decreased ceramide-induced lipotoxicity
and ER stress might mediate the central actions of THs on liver
and BAT metabolism, we ICV treated hyperthyroid rats with C6
ceramide. Central administration of ceramide induced a marked
feeding-independent weight gain (Figure 6A), which was associ-
ated with increased ceramide levels (hyperthyroid vehicle,
100% ± 6.37%; hyperthyroid ceramide ICV, 148.45% ± 4.70%;
p < 0.001) and the UPR in theMBH (Figure S6A) and, importantly,
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Figure 4. Effect of Deletion of AMPKa1 in SF1 Neurons in Liver and BAT
(A–C) Body weight (A), food intake (B), and fat depot mass (C) of SF1-Cre AMPKa1flox/flox mice (n = 15–25 mice/group).
(D) Cumulative EE of SF1-Cre AMPKa1flox/flox mice (n = 5–6 mice/group).
(E) 18F-FDG uptake analysis of SF1-Cre AMPKa1flox/flox mice (n = 5–6 mice/group).
(F) Infrared thermal images and quantification of temperature of BAT skin area of SF1-Cre AMPKa1flox/flox mice (n = 9–23 mice/group).
(G) BAT SNA of SF1-Cre AMPKa1flox/flox mice (n = 7–8 mice/group).
(H) mRNA levels of BAT genes of SF1-Cre AMPKa1flox/flox mice (n = 8 mice/group).
(I) Protein levels of thermogenic markers and proteins involved in lipolysis in the BAT of SF1-Cre AMPKa1flox/flox mice (n = 7 mice/group).
(J) Protein levels of AMPK pathway in the liver of SF1-Cre AMPKa1flox/flox mice (n = 7 mice/group).
(K) TG levels in the liver of SF1-Cre AMPKa1flox/flox mice (n = 9–10 mice/group).
*p < 0.05, **p < 0.01, ***p < 0.001, SF1-Cre AMPKa1flox/flox versus AMPKa1flox/flox. Data are expressed asmean ± SEM. The bands in gels from (I) and (J) have been
spliced from the same original gels. iWAT, inguinal WAT; gWAT, gonadal WAT; vWAT, visceral WAT. See also Figure S4.
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with decreased UCP1 protein levels (Figure 6B) and AMPK
signaling (Figure 6C) in the BAT. These data demonstrate that
central ceramide administration reversed the effect of central
T3 on BAT metabolism. Of note, no changes were found when
the AMPK pathway was assayed in the liver (Figure 6D), indi-
cating that the effect on BAT function is specific. To control the
effect of ceramide, we initially performed ICV administration of
C6-dihydroceramide (C6-DHC, an inactive form, used as a
negative control) to hyperthyroid rats. C6-DHC did not increase
either body weight or food intake (Figure S6B) or modulate BAT
or hepatic metabolism (Figures S6C–S6E) when compared with
ceramide treatment. Finally, we treated hyperthyroid rats with
adenoviruses overexpressing serine palmitoyltransferase long
chain base subunit 1 and 2 (SPTLC1-2, a rate-limiting enzyme
in ceramide synthesis pathway) into the VMH. As above, the
specificity of the injections was verified by the expression of
GFP in the VMH and the increased (2-fold) ceramide levels in
that area after adenoviral treatment (GFP, 100% ± 13.2%;
SPTLC1-2, 220.31% ± 79.88%; p < 0.05). The findings recapitu-
late those we observed with central administration of ceramide:
feeding-independent weight gain (Figure S6F), increased ER
stress in the VMH (Figure S6G), and decreased AMPK activation
and UCP1 expression in BAT (Figures S6H and S6I), without
affecting hepatic AMPK pathway (Figure S6J).
To assess the role of ER stress, we targeted GRP78 using
an adenoviral vector encoding a dominant-negative isoform
Figure 5. Effect of THs and AMPK on Hypothalamic Ceramides or ER Stress
(A–C) Ceramide levels (A), mRNA levels of the enzymes involved in the metabolism of complex lipids (B), and protein levels of the UPR in the hypothalamus of
euthyroid or hyperthyroid rats (n = 8–15 rats/group) (C).
(D) Protein levels of the UPR in the MBH of rats ICV treated with vehicle or T3 (n = 7 rats/group).
(E and F) Protein levels of the UPR (E) and ceramide levels in the VMH of rats treated in the VMH with vehicle or T3 (n = 7–10 rats/group) (F).
(G and H) Protein levels of the UPR (G) and ceramide levels in the VMH of rats treated in the VMHwith GFP-expressing adenoviruses or adenoviruses encoding a
AMPKa-DN (n = 7–9 rats/group) (H).
(I) Protein levels of the UPR in the VMH of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or AMPKa-CA (n = 7 rats/group).
(J) Protein levels of the UPR in the VMH of SF1-Cre AMPKa1flox/flox (n = 7–14 rats/group).
*p < 0.05, **p < 0.01, ***p < 0.001 versus euthyroid, vehicle ICV, vehicle VMH, and GFP or hyperthyroid GFP versus hyperthyroid AMPKa-CA or SF1-Cre
AMPKa1flox/flox versus AMPKa1flox/flox. Data are expressed as mean ± SEM. The bands in gels from (C)–(E), (G), (I), and (J) have been spliced from the same
original gels. See also Figure S5.
Figure 6. Effect of Hypothalamic Ceramide-Induced Lipotoxicity and ER Stress on the Central Action of THs on Liver and BAT
(A) Body weight change and food intake of hyperthyroid rats ICV treated with vehicle or C6 ceramide ICV (n = 9–10 rats/group).
(B–D) Protein levels of UCP1 in the BAT (B) and the AMPK pathway in the BAT (C) and liver (D) of hyperthyroid rats ICV treated with vehicle or C6 ceramide ICV
(n = 7 rats/group).
(E) Body weight change and food intake of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or GRP78-DN (n = 22–25 rats/group).
(F–H) Protein levels of UCP1 in the BAT and the AMPK pathway in the BAT and liver of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or
GRP78-DN (n = 13–15 rats/group).
*p < 0.05, **p < 0.01, ***p < 0.001 versus hyperthyroid vehicle ICV or hyperthyroid GFP VMH. Data are expressed as mean ± SEM. The bands in gels from (C), (F),
and (G) have been spliced from the same original gels. See also Figure S6.
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(GRP78-DN), which was injected into the VMH. Administration of
GRP78-DN adenovirus into the VMH of hyperthyroid rats
promoted feeding-independent weight gain (Figure 6E) asso-
ciated with increased ER stress in the VMH (Figure S6K),
reduced UCP1 levels (Figure 6F), and AMPK signaling in BAT
(Figure 6G). No changes were detected in hepatic AMPK
signaling (Figure 6H). Altogether, this evidence suggests that
ceramide levels and ER stress in the VMH mediate the actions
of T3 and AMPK on BAT, but not on liver metabolism.
JNK Inhibition Reverses the Central Actions of T3 on
Liver, but Not on BAT
Recent evidence has shown that hypothalamic protein kinase C
(PKC) plays a major role in the regulation of hepatic glucose
metabolism through the ANS (Benoit et al., 2009). We found
that PKCd, but not PKCε, protein levels were elevated in the hy-
pothalamus or the MBH of hyperthyroid and ICV T3-treated rats,
respectively (Figures S7A and S7B), indicative of a potential role
of PKCd in T3 action. To examine this further, we used the PKC
inhibitor rottlerin that, when given centrally, decreased protein
levels of PKCd and its downstream target, phosphorylated extra-
cellular-signal-regulated kinase (pERK) (Figure S7C). However,
our data showed no impact of rottlerin on hepatic pAMPK and
pACC protein levels either in hyperthyroid or ICV T3-treated
rats (Figures S7D and S7E), indicating that PKC pathway was
not involved in the central actions of THs on liver.
c-Jun N-terminal kinase 1 (JNK1) plays a crucial role in the hy-
pothalamic regulation of feeding and glucose metabolism (Sabio
et al., 2010; Vernia et al., 2013; Tsaousidou et al., 2014). We
analyzed JNK protein levels in the hypothalamus of hyperthy-
roid, ICV T3-treated, and VMH T3-treated rats. Interestingly,
the protein levels of phosphorylated JNK (pJNK) were increased
in the hypothalamus, MBH, and VMH, respectively, of those
models (Figures 7A–7C). Furthermore, the effect of hyperthy-
roidism and T3 on pJNK was reversed when rats were simul-
taneously treated with AMPKa-CA into the VMH, indicating
that the effect of THswasmediated by AMPK, which is upstream
of JNK (Figures 7D and 7E). SF1-Cre AMPKa1flox/flox mice
showed increased pJNK protein levels in the VMH, therefore
recapitulating the effects of THs (Figure 7F).
We also tested whether JNKmight mediate the central actions
of T3 on liver lipogenesis using the JNK inhibitor SP600125 (Im-
bernon et al., 2013). When given centrally, SP600125 decreased
the MBH levels of phosphorylated c-Jun (p-c-Jun) and signal
transducer and activator of transcription 3 (pSTAT3), indicating
functional inhibition of JNK (Figure S7F). Of note, SP600125
did not interfere with the central effect of T3 on pAMPK in the
MBH (Figure S7G), confirming that JNK was not upstream of
AMPK. In addition, SP600125 treatment did not revert the cen-
tral actions of T3 on either BAT UCP1 or AMPK pathway protein
levels (Figures S7H and S7I). However, SP600125 was also
able to reverse the central actions of T3 on the hepatic AMPK
pathway, as indicated by the increased pAMPK and pACC
protein levels (Figure S7J), alongside a reduction in lipid and
TG content (Figures S7K and S7L), indicating that the effect
was liver specific.
JNK1 in the VMH Mediates the Central Actions of T3 on
Liver, but Not on BAT
Central T3 elicited feeding-independent weight loss in both
wild-type (WT) and jnk1 null (JNK1 KO) mice (Figure 7G) and
decreased AMPK signaling in the liver of WT mice (Figure 7H),
but not in JNK1 KOmice (Figure 7I). In line with this, hepatic lipid
and TG content (Figures 7J and 7K) was elevated in WT, but not
in JNK1 KO mice. Notably, AMPK signaling was decreased in
the ventromedial hypothalamus of both WT and JNK1 KO (Fig-
ure S7M), consistent with the observation above that AMPK is
upstream of JNK1. UCP1 protein levels in BAT were increased
by T3 in both WT and JNK1 KO mice (Figure S7N), suggesting
that JNK1 mediated the actions of THs on liver, but not on BAT
function.
We repeated the experiment using global jnk2 null (JNK2 KO)
mice, which also carry floxed alleles of the jnk1 gene. We treated
these mice in the VMH with adeno-associated viruses (AAVs)
expressing GFP or the Cre-recombinase before ICV administra-
tion of T3, meaning that a group of jnk2 null mice have normal
jnk1 and the ones treated with the Cre-recombinase have
VMH-specific deletion of jnk1 gene. The infection efficiency
was demonstrated by decreased levels of p-c-Jun and pSTAT3
in the VMH of Cre-treated mice, indicating functional inhibition of
Figure 7. Effect of JNK1 in the VMH on the Central Actions of T3 on Liver and BAT
(A) Protein levels of JNK and pJNK in the hypothalamus of euthyroid and hyperthyroid rats (n = 7 rats/group).
(B) Protein levels of JNK and pJNK in the MBH of rats ICV treated with vehicle or T3 (n = 7 rats/group).
(C) Protein levels of JNK and pJNK in the VMH of rats treated in the VMH with vehicle or T3 (n = 7 rats/group).
(D) Protein levels of JNK and pJNK in the VMH of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or AMPKa-CA (n = 7 rats/group).
(E) Protein levels of JNK and pJNK in the VMH of rats ICV treated with vehicle or T3 and treated in the VMH with adenoviruses encoding GFP or AMPKa-CA
(n = 11 rats/group).
(F) Protein levels of JNK and pJNK in the VMH of SF1-Cre AMPKa1flox/flox mice (n = 7 mice/group).
(G) Body weight change and food intake of wild-type (WT) and JNK1 KO mice ICV treated with vehicle or T3 (n = 12–16 mice/group).
(H and I) Protein levels of the AMPK pathway in the liver of WT (H) or JNK1 KO mice (I) ICV treated with vehicle or T3 (n = 12–16 mice/group).
(J and K) Oil Red O (403; scale bar, 50 mm) staining analysis (J) and TG levels in the liver of WT or JNK1 KO mice ICV treated with vehicle or T3 (n = 11–
15 mice/group) (K).
(L) Body weight change and food intake of JNK2 KO-JNK1flox/flox mice ICV treated with vehicle or T3 and treated in the VMH with AAV expressing GFP or Cre
(n = 9-12 mice/group).
(M and N) Protein levels of the AMPK pathway in the liver of JNK2 KO-JNK1 floxedmice ICV treatedwith vehicle or T3 and treated in the VMHwith AAV expressing
GFP (M) or Cre (N) (n = 9–12 mice/group).
(O and P)Oil RedO (403; scale bar, 50 mm) staining analysis (O) and TG levels in the liver of JNK2KO-JNK1flox/floxmice ICV treatedwith vehicle or T3 and treated in
the VMH with AAV expressing GFP or Cre (n = 6–12 mice/group) (P).
*p < 0.05, **p < 0.01, ***p < 0.001 versus euthyroid, vehicle ICV, vehicle VMH,GFP VMH, and T3 ICV vehicle ICV. Data are expressed asmean ± SEM. The bands in
gels from (A)–(F), (H), (I), (M), and (N) have been spliced from the same original gels. See also Figure S7.
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JNK1 (Figure S7O). ICV T3 decreased body weight in a feeding-
independent manner in both groups (Figure 7L) and the AMPK
signaling pathway in the liver of JNK2 KO-JNK1flox/flox mice
that received AAV-expressing GFP (Figure 7M). However, the ef-
fect of central T3 on liver was totally absent in themice previously
treated with AAV-Cre in the VMH (Figure 7N). Accordingly, T3
increased lipid and TG content (Figures 7O and 7P) in the liver
of GFP-, but not Cre-treated, mice. Consistent with our findings
in the JNK1 KOmice, T3 decreased pAMPK levels in the VMH of
both models (Figure S7P) and increased UCP1 protein levels in
BAT (Figure S7Q). Overall, these data indicate that JNK1 in the
VMH mediates the central T3 actions on hepatic lipogenesis,
but not BAT function.
DISCUSSION
THs regulate lipid synthesis in liver, muscle, WAT, BAT, and hy-
pothalamus bymodulating expression and activation of key lipo-
genic enzymes such as ACC, FAS, and AMPK (Lo´pez et al.,
2013; Mullur et al., 2014), as well as autophagy (Sinha et al.,
2012). Although relevant effects of THs on energy balance
have been reported, the central action of THs on peripheral lipid
metabolism remains uncertain. This question is of interest for
several reasons. First of all, very recent evidence shifted the
‘‘classical’’ view of the mode of action from ‘‘peripheral perspec-
tive’’ (Silva, 2006) to a ‘‘central perspective’’ (Fliers et al., 2010;
Warner and Mittag, 2012; Lo´pez et al., 2013), recognizing the
brain as a major mediator of the metabolic actions of THs. Sec-
ond, dysregulation of the thyroid axis in humans leads to marked
alterations in energy balance; for example, up to 85% of patients
with hyperthyroidism exhibit weight loss despite increased food
intake (Silva, 2006; Lo´pez et al., 2013). Moreover, hyperthyroid
patients show increased hepatic lipogenesis (Cachefo et al.,
2001), enhanced lipolysis, and TG and FA cycling, which
contribute to higher EE (Beylot et al., 1991). Third, the potential
of THs as a target in the treatment of obesity has been known
for decades and recent evidence has placed glucagon-T3 conju-
gates in the possible pipeline for obesity treatment (Finan et al.,
2016). Thus, the precise understanding of the central actions of
T3 on metabolism is necessary for the development of therapies
for obesity, but also for TH-associated metabolic disorders.
We focused on the contribution of the central effects of THs
to the lipid alterations observed in the hyperthyroid state. Our
data showed that, when administered centrally, T3 promotes
the same pattern of expression in pro-lipogenic enzymes as
observed in the hyperthyroid liver and BAT. Notably, these ac-
tions specifically target the VMH. Indeed, administration of the
hormone into the ARC did not recapitulate the effects on liver
and BAT lipogenic programs evoked by VMH T3. Recent evi-
dence has substantially expanded our understanding of the
metabolic roles of the VMH, demonstrating extensive function-
ality of this hypothalamic area in the control of food intake (Dhil-
lon et al., 2006), EE (Lo´pez et al., 2010; Xu et al., 2011b; Martı´nez
de Morentin et al., 2014; Contreras et al., 2014), and peripheral
glucose homeostasis (Tong et al., 2007). Of note, many of those
effects also appear to involve one specific neuronal population of
the VMH, namely SF1 neurons, the same population where
AMPK conducts its actions on BAT and liver metabolism. This
is based on our finding that SF1 neuron-specific ablation of the
AMPKa1 isoform, which is downregulated by THs (Lo´pez et al.,
2010), entirely recapitulates the central effects of T3 on energy
balance. Altogether, this evidence demonstrates that SF1 neu-
rons of the VMH mediate the central effect of THs on meta-
bolism. Although nearly all VMHneurons express SF1, numerous
subpopulations can be distinguished based on their differential
expression of several proteins, including brain-derived neuro-
trophic factor (Segal et al., 2005), insulin and leptin receptors
(Klo¨ckener et al., 2011; Dhillon et al., 2006), estrogen receptor
a (Xu et al., 2011b), and vesicular glutamate transporter 2
(VGLUT2) (Tong et al., 2007; Cheung et al., 2015). Besides
that, SF1 neurons project broadly within the CNS. They send
axons to the C1 catecholamine cell group of the rostral ventrolat-
eral medulla (RVLM), which controls the sympathetic outflow to
BAT (Lindberg et al., 2013; Morrison et al., 2014). Neuronal fibers
originating from the VMH SF1 neurons also reach other hypotha-
lamic regions involved in SNS and PSNS outflow, including the
ARC and PVH (Lindberg et al., 2013; Morrison et al., 2014).
Notably, specific ablation of VGLUT2 in SF1 neurons has been
shown to impair neuronal activation in the DMV (Tong et al.,
2007), a key site that gives rise to the PSNS fibers innervating
the liver (Fliers et al., 2010). That heterogeneity could explain
the ability of these neurons to control both the SNS and the
PSNS, although it is likely that the neuronal circuits modulating
both branches of the ANS may involve separate subpopulations
of SF1 neurons.
We have also defined the exact downstreammechanisms link-
ing AMPK in the VMH with peripheral metabolism. We provide
evidence that a T3-induced decrease in AMPK in the VMH pro-
motes a dichotomic mechanism involving ceramide-ER stress
and JNK1 to modulate BAT and liver function, respectively.
Recent data have shown that ceramide-induced lipotoxicity
and ER stress lead to decreased thermogenesis and weight
gain (Contreras et al., 2014). Our data show that a T3-induced
reduction in AMPK activity promotes decreased hypothalamic
ceramide concentration and subsequent reduction in ER stress.
Of note, augmented ceramide levels in the cortex lead to
increased ER stress at this level, which suggests that THs induce
regional modulation of lipid metabolism and ER stress in the
brain. The mechanistic role of ceramides on the hyperthyroid
phenotype was demonstrated by administration of C6 ceramide,
overexpression of SPTCL1-2 in the VMH, and a specific increase
of ER stress in the VMH by GRP78-DN, all of which blocked TH
actions on BAT, but not on liver. Overall, these data suggest that
AMPK-induced changes in ceramides and ER stress, specifically
in the VMH, mediate the central actions of THs on BAT and
energy balance. Although the precise mechanism whereby T3
regulates AMPK signaling is yet to be elucidated, our previous
findings have clearly demonstrated that this effect is mediated
by TRa1 (Lo´pez et al., 2010). Considering the rapid time course
of TH effects we report, it is tempting to speculate that non-
genomic actions through the membrane-bound TRa (Kalya-
naraman et al., 2014) or the mitochondrial TRa isoform p43
(Sayre and Lechleiter, 2012) could contribute to the regulation
of AMPK. However, using a transgene mouse for a GFP-tagged
TRa, it has been demonstrated that at least in the brain all
T3-binding isoforms from this receptor are nuclear (Wallis
et al., 2010). Consequently, since our observations are still within
the timeframe of T3-mediated genomic actions, which can be
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observed as early as 1–3 hr in vivo (Izquierdo and Cuezva, 1993;
Erion et al., 2007), it seems most likely that T3 modulates AMPK
signaling through TRa1-mediated changes in gene transcription,
a possibility that is further supported by the decreased AMPKa1
(total, non-phosphorylated) protein levels in the hypothalamus
after T3 and T4 treatments (Lo´pez et al., 2010). Another impor-
tant question is how modulation of ER stress and ceramides
could be connected to changes in neuronal activity. It has
been reported that ER stress causes altered calcium signaling
in neurons by impairing the activity of ER-resident calcium-
release channels and inositol 1,4,5-trisphosphate receptor
(IP3R); notably, GRP78 (which is increased in the hypothalamus
after THs treatments) plays a protective role (Narayanan et al.,
2010; Higo et al., 2010). The interaction of ER and mitochon-
dria, which modulates neuronal excitability, is another potential
mechanism. For example, ablation of mitofusin 2 (MFN2), which
results in loss of ER-mitochondria contacts, increases ER stress
and decreases neuronal firing (Dietrich et al., 2013; Schnee-
berger et al., 2013). Whether central T3 impacts the ER-mito-
chondria connection in hypothalamic neurons is presently un-
known, but further work is warranted.
We present conclusive evidence that T3 regulates hepatic
lipogenic pathway by modulating AMPK and JNK1, specifically
in the VMH, leading to hepatic vagal activation, as supported
by VGX experiments. The positive effect of JNK1 on neuronal
activation has been previously described in AgRP neurons
(Tsaousidou et al., 2014). The molecular mechanisms underlying
this action are unclear, but it is known that JNK1 regulates
several processes related to brain morphogenesis, neuronal ac-
tivity, axo-dendritic architecture, and synaptic plasticity (Sherrin
et al., 2010; Xu et al., 2011a; Mohammad et al., 2017). The net
result of central T3 is a PSNS-mediated increase of the lipogenic
rate in the liver. In this regard, our data demonstrate that de novo
FA synthesis and uptake into liver are increased and incorpo-
rated into TGs. The concomitant increase in the appearance of
14C in BAT is consistent with the data showing that central (ICV
or VMH) T3 increases the thermogenic program in this tissue,
the glucose uptake, and the mitochondrial activity and dy-
namics, leading to increased EE and decreased RQ. Since THs
modulate FA uptake in a tissue-specific manner (Klieverik
et al., 2009), it is likely that the 14C in BAT arises from both direct
uptake of circulating FA (Ouellet et al., 2012) and hepatic TG in
the form of TG-rich lipoproteins (TRLs) that are known to
contribute greatly to BAT lipid content during thermogenesis
(Bartelt et al., 2011). Therefore, T3 acts within the VMH in a
manner that seems to maximize the metabolic capacities of
each organ, leading to an overall effect of negative energy bal-
ance and weight loss, despite unchanged food intake.
In summary, central T3 regulates hepatic metabolism through
the vagus nerve and BAT through the SNS, leading to increased
lipid oxidation and thermogenesis. This physiological pathway is
mediated by AMPK (specifically in SF1 neurons of the VMH),
which also exerts a dichotomic action on ceramide-induced
ER stress and JNK1. Overall, our results uncover the intercon-
nected nature of these mechanisms in terms of TH actions at
the whole-body level to regulate organism lipid handling and
their relevance to energy and metabolic homeostasis. This
knowledge should aid in the more rationally based design of
drugs for the treatment of obesity and its comorbidities.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal Anti-AcetylCoA Carboxylase 1 Merck Millipore 04-322; RRID: AB_673047
Rabbit polyclonal Anti-AMPKa1 Merck Millipore 07-350; RRID: AB_310542
Rabbit polyclonal Anti-AMPKa2 Merck Millipore 07-363; RRID: AB_310553
Rabbit Anti-IRE1 a (14C10) Cell Signaling Technology 3294S; RRID: AB_823545
Rabbit monoclonal Anti-phospho-AMPK a (Trh172) Cell Signaling Technology 2535S; RRID: AB_331250
Rabbit monoclonal Anti-PERK (C33E10) Cell Signaling Technology 3192S; RRID: AB_2095847
Rabbit polyclonal Anti-Phospho-AcetylCoA
Carboxylase (Ser79)
Cell Signaling Technology 3661; RRID: AB_330337
Rabbit monoclonal Anti-p-SAPK/JNK (T183/Y185) Cell Signaling Technology 4671S; RRID: AB_331338
Rabbit Anti-Phospho-HSL (S660) Cell Signaling Technology 4126S; RRID: AB_490997
Rabbit Anti-P-c-Jun (S63) Cell Signaling Technology 9261L; RRID: AB_2130159
Rabbit Anti-GRP78 Cell Signaling Technology 3183S; RRID: AB_10695864
Rabbit monoclonal Anti P-p44/42 MAPK (Anti-pERK) Cell Signaling Technology 4370; RRID: AB_2315112
Rabbit Anti-Phospho-Stat3 (Ser727) Cell Signaling Technology 9134S; RRID: AB_331589
Mouse monoclonal Anti-Fatty Acid Synthase BD Biosciences 610963; RRID: AB_398276
Rabbit Anti-ATF6 a (H-280) Santa Cruz Biotechnology sc-22799; RRID: AB_2242950
Rabbit Anti-GADD 153 (R-20) Santa Cruz Biotechnology sc-793; RRID: AB_2242950
Rabbit Anti-Phospho-eIF2 a (Ser52) Santa Cruz Biotechnology sc-101670; RRID: AB_631364
Rabbit Anti-Phospho-PERK (Thr981) Santa Cruz Biotechnology sc-32577; RRID: AB_2293243
Rabbit polyclonal Anti-JNK1/3 (C-17) Santa Cruz Biotechnology sc-474; RRID: AB_632383
Mouse monoclonal Anti-PKC d (G-9) Santa Cruz Biotechnology sc-8402; RRID: AB_628145
Rabbit polyclonal Anti-NFkB p65 (C-20) Santa Cruz Biotechnology sc-372; RRID: AB_632037
Rabbit polyclonal Anti-p-IKKa/b Santa Cruz Biotechnology sc-23470-R; RRID: AB_2122159
Rabbit polyclonal Anti-c-FOS Santa Cruz Biotechnology sc-52; RRID: AB_2106783
Mouse monoclonal Anti-a-tubulin Sigma-Aldrich T5168; RRID: AB_477579
Mouse monoclonal Anti-b-Actin Sigma-Aldrich A5316; RRID: AB_476743
Rabbit Anti-Phospho-IRE1 a (Ser724) Abcam ab48187; RRID: AB_873899
Rabbit polyclonal Anti-UCP1 Abcam ab10983; RRID: AB_2241462
Rabbit polyclonal Anti-UCP3 Abcam ab3477; RRID: AB_2304253
Rabbit polyclonal Anti-Hormone sensitive lipase Abcam ab45422; RRID: AB_2135367
Rabbit monoclonal Anti-PKC ε Abcam ab124806; RRID: AB_10973051
Rabbit polyclonal Anti-SPTLC2 Abcam ab23696; RRID: AB_447617
Rabbit polyclonal Anti-SPTLC1 Abcam ab84585; RRID: AB_2195858
Rabbit polyclonal Anti-IL6 Abcam ab6672; RRID: AB_2127460
Mouse monoclonal Anti-IBA1 Abcam ab15690; RRID: AB_2224403
Bacterial and Virus Strains
Adenoviral GFP (Lo´pez et al., 2010; Martı´nez
de Morentin et al., 2014)
Viraquest N/A
Adenoviral GFP (Lo´pez et al., 2010; Martı´nez
de Morentin et al., 2014)
Signagen N/A
Adeno-associated GFP (In this paper) Signagen N/A
Adenoviral AMPKa-DN (Lo´pez et al., 2010; Martı´nez
de Morentin et al., 2014)
Viraquest N/A
Adenoviral AMPKa-CA (Lo´pez et al., 2010; Martı´nez
de Morentin et al., 2014)
Viraquest N/A
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Adenoviral GRP78-DN (Contreras et al., 2014) Viraquest N/A
Adenoviral TR-DN (Lo´pez et al., 2010) Viraquest N/A
Adenoviral SPTLC1-2 (In this paper) Viraquest N/A
Adeno-associated Cre (In this paper) Signagen N/A
Chemicals, Peptides, and Recombinant Proteins
L-thyroxine sodium salt pentahydrate Sigma-Aldrich T2501
Xylazin hydrochloride Rompun (Bayer) N/A
Ketamine (for experiments in University of Santiago,
Spain)
Imalgene (Elasa) N/A
Ketamine (for experiments in University of Iowa, USA) Akorn (Lake Forest, IL USA) N/A
Isoflurane BAXTER SL NR60378
Oxygen Air Liquide SLU ESGCG101710035000
3,30,5-Triiodo-L-thyronine Sigma-Aldrich T2877
N-Hexanoyl-D-sphingosine (C6 ceramide) Sigma-Aldrich 6524
SR59230A hydrochloride Tocris Bioscience 1511
C6-DHC (C6-dihydroceramide) Sigma-Aldrich C8230
JNK inhibitor SP600125 Tocris Bioscience 1496
Rottlerin Calbiochem 557370
DMEM Low glucose (Supplemented with glucose
up to 4,5g/L)
Sigma-Aldrich 2905
DMEM without sodium bicarbonate GIBCO, Life Technologies 12800-058
Albumin Fraction V (Fatty acid free) Roche 10775835001
Insulin (Insulated FlexPen 100Ul/ml) Novo nordisk 8-9657-51-202-3
Palmitic Acid Sigma-Aldrich P0500
Hionic Fluor (Scintillation Cocktail) Perkin Elmer 6013319
Cocktail Biogreen3 for liquid scintillation Scharlau CO015005P
Acetic acid sodium salt [3H] (0,1Ci/mmol) Perkin Elmer NET003
Palmitic acid [1-14C] (56,1mCi/mmol) Perkin Elmer NEC075H
Perchloric acid Scharlau AC17601000
Natriumacetat-trihydrat Merck K34638967518
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich D8418
Sodium pyruvate GIBCO, Life Technologies SH30239.01
L-glutamine GIBCO, Life Technologies 25030-024
Succinate Sigma-Aldrich S9512
Rotenone Sigma-Aldrich R8875
2-18F-Fluoro-2-Deoxy-2-Glucose (18F-FDG) GALARIA Centro PET S.L. Batch 5676234521
FDG Cassette ABX Advanced Biochemical
Compounds
http://www.abx.de/
EMbed 812 resin Electron Microscopy Sciences EMS 14120
Food industry FAME mix Restek Corporation 35077
Supelco 46904 Vaccenic Methyl ester Sigma-Aldrich CRM46905
N-lauroyl-D-erythro-sphingosine. C12 Ceramide
(d18:1/12:0)
Avanti Polar Lipids 860512P
N-palmitoyl-D-erythro-sphingosine C16 Ceramide
(d18:1/16:0)
Avanti Polar Lipids 860516P
N-heptadecanoyl-D-erythro-sphingosine C17
Ceramide (d18:1/17:0)
Avanti Polar Lipids 860517
N-stearoyl-D-erythro-sphingosine C18 Ceramide
(d18:1/18:0)
Avanti Polar Lipids 860518P
(Continued on next page)
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N-lignoceroyl-D-erythro-sphingosine. C24 Ceramide
(d18:1/24:0)
Avanti Polar Lipids 860524P
N-nervonoyl-D-erythro-sphingosine. C24:1 Ceramide
(d18:1/24:1(15Z))
Avanti Polar Lipids 860525P
Alpha-chloralose MP Biomedical (Solon, OH, USA) 100459
14C labeled 2-Deoxy-Glucose (Deoxy-D-glucose,
2-[14C(U)]
Perkin Elmer NEC720A050UC
Dako EnVision system, peroxidase Dako K5007
Oil Red O solution Sigma-Aldrich O1391
Harris’ Hematoxylin Bio-Optica 05-06005/L
Mount Quick Aqueous Bio-Optica 05-1740
Trizol Reagent Invitrogen 15596018
M-MLV enzyme Invitrogen 28025- 013
35S- adATP Perkin Elmer NEG 0345
Terminal deoxynucleotidil transferase New England Biolabs MO315S
Deionited Formamide Sigma-Aldrich F9037
Denhardt’s solution Sigma-Aldrich D2532
Dextran Sulfate Sigma-Aldrich D8906
Fixator (Manual Fixing Bath) AGFA G354
Developer (Replenisher) AGFA G150
Sheared Single- Stranded Salmon Sperm DNA Sigma-Aldrich D9156
Tri- Sodium Citrate dihydrate MERCK A73548612
Ethylene glycol-bis(2-aminoethylether)-N,N,N0,
N0-tetraacetic acid (EGTA)
Sigma-Aldrich E3889-500G
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich E9884-500G
Triton X-100 Sigma-Aldrich X100-500ml
Sodium orthovanadate: Sigma-Aldrich S6508-50G
Sodium fluoride Sigma-Aldrich S7920-100G
Sodium pyrophosphate Sigma-Aldrich 221368-500G
Sucrose Sigma-Aldrich S0389
Protease Inhibitor Cocktail Tablets Roche Dieagnostics 11697498001
Protein Assay Dye Reagent Concentrate (Bradford) Bio-Rad 500- 0006
30% Acrilamide/ Bis Solution 29:1 Bio- Rad 161- 0156
Critical Commercial Assays
Fatty acids Kit Wako chemicals R1: 434-91795; R2: 436-91995
TG kit Spinreact 1001314
ELISA FGF21 mouse/rat Biovendor RD291108200R
Ketone kit Wako chemicals R1: 415-73301; R2: 413-73601
TSH ELISA Kit Crystal Chem 80564
T3 ELISA Kit Crystal Chem 80985
T4 ELISA Kit Crystal Chem 80983
Experimental Models: Organisms/Strains
Sprague-Dawley rats Animalario Central USC (Spain) N/A
Sprague-Dawley rats (for experiments in University
of Iowa, USA)
Harlan Sprague-Dawley
(Indianapolis, IN, USA)
Model 002; RRID: RGD_70508
JNK1 KO: B6.129S1-Mapk8tm1Flv/J (in the paper:
null Jnk1 mice)
Howard Hughes Medical Institute
(Dr. Roger J Davis) and CNIO
(Dr. Guadalupe Sabio)
RRID: IMSR_JAX:004319
JNK2 KO-JNK1flox/flox:B6.129-Mapk8LoxP/LoxP
Mapk9m1Flv/J (in the paper: null Jnk2 and Jnk1flox/flox)
Howard Hughes Medical Institute
(Dr. Roger J Davis) and CNIO
(Dr. Guadalupe Sabio)
N/A
(Continued on next page)
e3 Cell Metabolism 26, 212–229.e1–e12, July 5, 2017
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
C57BL/6 wildtype Fundacio´n Centro Nacional de
Investigaciones Cardiovasculares
Carlos III (Madrid, Spain)
N/A
SF1-Cre AMPKa1flox/flox In this paper N/A
Mixed Background AMPKa1flox/flox In this paper N/A
Mouse SF1-Cre:(Tg(Nr5a1-cre)Lowl/J The Jackson Laboratory JAX: 012462; RRID: IMSR_JAX:012462
Mouse AMPKa1flox/flox: Prkaa1tm1.1Sjm/J The Jackson Laboratory JAX: 014141; RRID: IMSR_JAX:014141
Oligonucleotides
Genotyping primer AMPKa1(Prkaa1) loxP site
Forward: 50-CCCACCATCACTCCATCTCT-30
Eurofins The Jackson laboratory (stock
number: 014141); NM_001013367
Genotyping primer AMPKa1 (Prkaa1) loxP site
Reverse: 50-AGCCTGCTTGGCACACTTAT-30
Eurofins The Jackson laboratory (stock
number: 014141); NM_001013367
Genotyping primer AMPKa1 (Prkaa1) deleted allele
Forward: 50-CCCACCATCACTCCATCTCT-30
Eurofins The Jackson laboratory (stock
number: 014141); NM_001013367
Genotyping primer AMPKa1 (Prkaa1) deleted allele
Reverse: 50-CCCACATAGGAAAGCGTGTT-30
Eurofins The Jackson laboratory (stock
number: 014141); NM_001013367
SF1-Cre transgene
Forward: 50-CTGAGCTGCAGCGCAGGGACAT-30
Eurofins The Jackson laboratory (stock
number: 012462); NC_000068.7
SF1-Cre transgene
Reverse: 50-TGCGAACCTCATCACTCGTTGCAT-30
Eurofins The Jackson laboratory (stock
number: 012462); NC_000068.7
In situ hybridization primer TRH 50- ATACCAGTTAG
GGTGAAGATCAAAGCCAGAGCCAGCAGCAACCAA-30
Eurofins NM_013046
In situ hybridization primer TRH (Trh) AMPKa1
(50- GCTCTCCTCCAGAGACATATTCCATCACCATGA-30
Eurofins NM_013046
RT-PCR primers See Table S1 N/A
Software and Algorithms
Bruker Albira Suite Software Version 5.0. Scatter Bruker Biospin https://www.bruker.com/
FLIR-Tools-Software FLIR http://www.flir.com/instruments/
display/?id=54865
ImageJ NIH https://imagej.nih.gov/ij/index.html;
RRID: SCR_003070
Xcalibur Thermo Fisher Scientific OPTON-2050; RRID: SCR_014593
MassLynx Waters http://www.waters.com/waters/
es_ES/MassLynx-Mass-Spectrometry-
Software-/nav.htm?cid=513164&locale=
es_ES; RRID: SCR_014271
MZmine 1 v.0.60 MZmine http://mzmine.github.io/download.html;
RRID: SCR_012040
Prism Graph Pad https://www.graphpad.com/scientific-
software/prism/; RRID: SCR_002798
AMIDE AMIDE http://amide.sourceforge.net/;
RRID: SCR_005940
LabChart (version 5) ADInstruments https://www.adinstruments.com;
RRID: SCR_001620
Other
Osmotic Minipump Durect Corporation
(Alzet Osmotic Pumps)
Model 2001
Osmotic Minipump Durect Corporation
(Alzet Osmotic Pumps)
Model 1007D
Osmotic Minipump Durect Corporation
(Alzet Osmotic Pumps)
Model 1004D
Stereotaxic Frame David Kopf Instruments Model 900
22-gauge needle Hamilton 1702N
(Continued on next page)
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25-gauge needle Hamilton 7001N
28-gauge stainless steel cannula (Imbernon et al., 2013;
Martı´nez-Sa´nchez et al., 2017)
Plastics One N/A
Polyethylene Tubes (PE50) Becton Dickinson and Company 427411
Polyethylene Tubes (PE20) Becton Dickinson and Company 427406
Whatman paper 3MM Chr GE Healthcare 3030-931
Catheter tubes Degania Medical 2110060149IZ
Seahorse Bioscience XF24-3 Extracellular Flux Analyzer Seahorse Bioscience
(Agilent technologies)
N/A
XF24-3 fluxpak Seahorse Bioscience
(Agilent technologies)
102070-001
XF24 Islet Capture Microplates Seahorse Bioscience
(Agilent technologies)
101122-100
Albira PET/CT Preclinical Imaging System Bruker Biospin https://www.bruker.com/
Multi-anode photomultiplier tubes Bruker Biospin https://www.bruker.com/
AMIDE medical imaging viewer Stanford University http://amide.sourceforge.net/
Calorimetric System LabMaster TSE Systems N/A
B335: Compact-Infrared-Thermal-Imaging-Camera FLIR N/A
HIP-511: High-impedance probe Grass Instruments N/A
P5 AC pre-amplifier. Grass Instruments N/A
Nerve traffic analysis system (Model 706C) University of Iowa Bioengineering N/A
Oscilloscope (model 54501A) Hewlett-Packard N/A
Resetting voltage integrator (Model B600c) University of Iowa Bioengineering N/A
JEM-1400 Transmission Electron Microscope Jeol N/A
Thermo Finnigan Focus GC Thermo Scientific N/A
Thermo Scientific TR-FAME column Thermo Scientific N/A
Thin-layer chromatography (TLC) silica sheets 20x20 cm Merck Millipore 1055530001
300SL Liquid Scintillation Counter LabLogic N/A
API 3000 PE Sciex LC-ESI-MS/MS System Spectralab Scientific N/A
OA-ToF Premier Mass Spectrometer Waters N/A
Q-ToF Premier Mass Spectrometer Waters N/A
UPLC/MS Waters N/A
Acquity UPLC BEH C8 Waters 186002878
Acquity UPLC BEH C18 Waters 186002350
7500 Real Time PCR System Thermo Fisher Scientific 4351105
PVDF transfer membrane MERCK Millipore IPVH00010
Olympus XC50 Olympus Corporation N/A
Olympus IX51 Olympus Corporation N/A
EcoMRI 700: Body Composition Analyzer EcoMRI Model 700
Cryostat Leica Biosystems CM 1850 UV
Serum Vacutainer BD 367957
Lock Spray Mass Ionization Source Waters N/A
Hyperfilm b-Max Amersham N/A
Medical X- Ray Film Fujifilm 47410 19289
BioMax MR Film Kodak 871 5187
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Adult male Sprague-Dawley rats (8-10 weeks old, 200-250 g; Animalario General USC, Santiago de Compostela, Spain), adult
male null Jnk1 mice (C57BL/6 background; 8-10 weeks old), adult male null Jnk2 and Jnk1flox/flox and their wild-type mice
(C57BL/6 background; 8-10 weeks old; Fundacio´n Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain),
and adult male null SF1-Cre AMPKa1flox/flox mice (mixed background; 20 weeks old; The Jackson Laboratory, Bar Harbor, ME, USA)
and their littermates were used. During all experimental approaches the animals were dailymonitored for food intake and bodyweight
changes, at the same hour. Protocols used for animals that received radiolabeled lipid were in accordance with the United Kingdom
Home Office legislation (Animal Scientific Procedure Act 1986). All the other experiments were performed in agreement with the
International Law on Animal Experimentation and were approved by the USC Ethical Committee (Project ID 15010/14/006) and
University of Iowa Institutional Animal Care and Use Committee.
To generate SF1 neuron-specific AMPKa1 knock-out mice (SF1-Cre AMPKa1flox/flox), SF1-Cre mice (Tg(Nr5a1-cre)Lowl/J, stock
number 012462; The Jackson Laboratory, Bar Harbor, ME, USA) were crossed with AMPKa1 floxed mice (AMPKa1flox/flox mice,
Prkaa1tm1.1Sjm/J; stock number 014141; The Jackson Laboratory; Bar Harbor, ME, USA) that possess loxP sites flanking exon 3
of Prkaa1 gene. Littermates of the same mixed background strain generation were used as controls. Animals were genotyped by
PCRwith the following set of primers: AMPKa1 loxP site: Forward: 50-CCCACCATCACTCCATCTCT-30, Reverse: 50-AGCCTGCTTGG
CACACTTAT-30; AMPKa1 deleted allele: Forward: 50-CCCACCATCACTCCATCTCT-30, Reverse: 50-CCCACATAGGAAAGCGTGTT-30
and SF1-Cre transgene: Forward: 50-CTGAGCTGCAGCGCAGGGACAT-30, Reverse: 50-TGCGAACCTCATCACTCGTTGCAT-30. The
deleted allele produced an amplicon of 530 bp.
Housing conditions
The animals were housed with an artificial 12 hr light (8:00 to 20:00)/12 hr dark cycle, under controlled temperature and humidity con-
ditions and allowed to free access to standard laboratory chow and tapwater. For all the procedures, the animals (rats andmice) were
caged individually, unless otherwise stated, and used for experimentation 5-7 days later. During this post-operative recovery period
the animals became accustomed to the handling procedure under non-stressful conditions. SF1-Cre AMPKa1flox/flox mice and their
littermates were housed in groups, except for food intake analyses, calorimetric system and the b3-AR antagonist experiment, for
which they were caged individually. During the induction of hyperthyroidism and VGX recovery time the rats were housed in groups
(4 rats/cage).
METHOD DETAILS
Induction of hyperthyroidism
Hyperthyroidism was induced by chronic subcutaneous (s.c.) administration of L-thyroxine (T4, 100 mg/day, dissolved in 200 mL of
saline; Sigma-Aldrich; St Louis, MO, USA) for a period of three weeks (21 days), as previously described (Lo´pez et al., 2010; Varela
et al., 2012; Martı´nez-Sa´nchez et al., 2017). Euthyroid (control) rats were treated with vehicle (saline).
Intracerebroventricular treatments
Intracerebroventricular (ICV) cannulae were stereotaxically implanted under ketamine/xylazine anesthesia or a mix of inhaled isoflur-
ane and oxygen, as previously described using the following coordinates 1.6 mm lateral to bregma, 0.6 mm posterior, 4.5 mm deep
(Lo´pez et al., 2010; Varela et al., 2012; Martı´nez deMorentin et al., 2014; Contreras et al., 2014). For the chronic experiments, rats and
mice received either a single ICV daily administration of triiodothyronine (T3; for rats 4 ng/day, during 5 days, dissolved in 5 mL of
saline; for mice 8 ng/day, during 5 days, dissolved in 1 mL of saline; Sigma-Aldrich; St Louis, MO, USA) at 20:00, just before turning
the light off (Lo´pez et al., 2010; Varela et al., 2012;Martı´nez-Sa´nchez et al., 2017). For the acute SNA recording, c-FOS analyses in the
DMV and 14C-oleate experiments rats received the same single dose of T3 or 1:50 saline:DMSO during 3 hr. The JNK inhibitor
SP600125 (Tocris Bioscience; Bristol, UK) was given ICV (0.5 mg/ml/day, dissolved in 15:50 saline:DMSO) (Imbernon et al., 2013) dur-
ing 7 days using osmotic minipump flow moderator (Model 2001; Alzet Osmotic Pumps, Cupertino, CA, USA). The PKC inhibitor,
rottlerin (Calbiochem; Billerica, USA) was given ICV (60 mmol/L, dissolved in saline) (Breen et al., 2011) for 7 days using osmotic mini-
pump flow moderator (Model 2001; Alzet Osmotic Pumps, Cupertino, CA, USA). The C6 ceramide (N-Hexanoyl-D-sphingosine) and
the C6-DHC (C6-dihydroceramide) were given ICV (1.25 mg/ml dissolved in saline containing 1/3 of DMSO; Sigma-Aldrich; St Louis,
MO, USA) or vehicle (saline containing 1/3 of DMSO; control rats) for 7 days using osmotic minipump flow moderator (Model 2001;
Alzet Osmotic Pumps, Cupertino, CA, USA) (Imbernon et al., 2013; Contreras et al., 2014).
14C-oleate infusions
Rats equipped with ICV cannulae were given 7 days to recover before infusions. Rats anesthetized with a-chloralose (2.5% solution,
50 mg/kg; MP Biomedical; Solon, OH, USA) were placed on heating pads before a catheter is inserted into the femoral vein. Anes-
thesia was infused (25 mg/kg/hr) alongside the 14C-oleate tracer (3000 Bq/min, total dose 0.6 MBq in 0.3 mmol of oleate; 14C labeled
2-Deoxy-Glucose (Deoxy-D-glucose, 2-[14C(U)]; Perkin Elmer, Waltham, MA, USA) (Klieverik et al., 2009). After 30 min baseline,
serummeasurements were taken and rats dosed with vehicle (DMSO) or T3 (4 ng for 3 hr, dissolved in 5 mL of DMSO; Sigma-Aldrich,
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St Louis,MO, USA) via ICV cannulae. Blood samples were taken at regular intervals until the experiment was terminated by sacrificing
the animals and collecting tissues.
Stereotaxic microinjection of T3 and viral vectors
Animals were placed in a stereotaxic frame (David Kopf Instruments; Tujunga, CA, USA) under ketamine/xylazine anesthesia. The
ARC and the VMH were targeted bilaterally using a 25-gauge needle (Hamilton; Reno, NV, USA). The injections were directed to
the following stereotaxic coordinates: a) for the VMH of rats: 2.8 mm and 3.2 mm posterior to the bregma, ± 0.6 mm lateral to midline
and 10.1 mm deep; b) for the VMH of mice: 1.7 mm posterior to the bregma, ± 0.5 mm lateral to midline and 5.5 mm deep c) for the
ARC of rats 2.8 mm posterior, ± 0.3 mm lateral to bregma and 10.2 mm deep. For acute treatments, T3 (Sigma-Aldrich, St Louis, MO,
USA; 16 ng in 1 mL of 1:50 saline:DMSO; during 12 hr) or vehicle (100 nL of 1:50 saline:DMSO) were given. For chronic nuclei-specific
treatments, T3 was given at 4 ng/day (in saline + 1 mM NaOH) and vehicle (saline + 1 mM NaOH) used as control. The selection of
these doses was based on previous reports (Lo´pez et al., 2010; Varela et al., 2012; Martı´nez-Sa´nchez et al., 2017). Nuclei-specific
injections were delivered via a permanent 28-gauge stainless steel cannula (Plastics One, Roanoke, VA, USA) inserted bilaterally
either in the VMH or ARC. A catheter tube was connected from each infusion cannula to an osmotic minipump flowmoderator (Model
1007D; Alzet Osmotic Pumps, Cupertino, CA, USA). These pumps had a flow rate of 0.5 mL/hour during 7 or 28 days of treatment. The
osmotic minipumps were inserted in a subcutaneous pocket on the dorsal surface created using blunt dissection and the treatment
was given for 7 or 28 days (Imbernon et al., 2013; Contreras et al., 2014).
Adenoviral (GFP, AMPKa-DN, AMPKa-CA, GRP78-DN, TR-DN and SPTLC1-2; Viraquest; North Liberty, IA, USA and SignaGen;
Rockville, MD, USA) or adeno-associated (Cre; SignaGen; Rockville, MD, USA) vectors were delivered in the VMH of rats or mice
using the aforementioned coordinates at a rate of 200 nl/min for 5 min for rat and 10 min for mouse (1 ml/injection site) as previously
reported (Lo´pez et al., 2010; Varela et al., 2012; Martı´nez de Morentin et al., 2014; Contreras et al., 2014). Animals were treated for
5-7 days (adenovirus) or 30 days (Cre).
Peripheral treatments
To test whether T3 ICV leaked to the periphery, T3 (Sigma-Aldrich; St Louis, MO, USA) was given intraperitoneally (IP; 4 ng/day,
dissolved in 200 mL of 1:50 saline:DMSO) during 4 days (Lo´pez et al., 2010). The adrenergic receptor beta 3 (b3-AR) specific antag-
onist SR59230A ([3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol-oxalate]; 3 mg/Kg/day dissolved
in saline:DMSO, 1:50 saline:DMSO; Tocris Bioscience; Bristol, UK) (Lo´pez et al., 2010; Martı´nez de Morentin et al., 2014) was admin-
istrated subcutaneously (s.c.) and animals were treated during 2 days before the T3 injections for rats and 7 days for SF1-Cre
AMPKa1flox/flox mice.
Vagotomy
To investigate the impact of the vagus nerve on T3 effects on hepatic metabolism, sham control and VGX rats were infused ICV or
VMHwith T3 at the doses previously described. The vagotomy surgical procedure was performed as previously described (Imbernon
et al., 2013). Briefly, under ketamine–xylazine anesthesia rats were placed on their backs and amidline abdominal incision wasmade.
The liver was then carefully moved to the right exposing the esophagus. Dorsal and ventral branches of the vagus nerve were
exposed and dissected from the esophagus. Each branch of the nerve was ligated with surgical suture at two points as distally
as possible to prevent bleeding, and then cauterized between the sutures. The abdominal muscles and the skin were then sutured
with surgical silk. Sham surgeries were also performed, in which each trunk of the nerve was exposed but not tied or cauterized. The
animals were allowed to recover for 15 days before other procedures. The effectiveness of the vagotomy was assessed at the end of
the study by post-mortem analysis of the stomach. Only the rats that showed an evident increase in stomach size after vagotomy (due
to motoric dysfunction) were included in the analysis (Imbernon et al., 2013).
Positron emission tomography–computed tomography
Chemicals
2-18F-Fluoro-2-Deoxy-2-Glucose (18F-FDG) was produced on a TRACERlab MX synthesizer (GE Healthcare; Little Chalfont, UK),
cassettes and reagent kits were fromABX (Advanced Biochemical Compounds, Radeberg, Germany) with the standardmethod sup-
plied fromGE (nucleophilic substitution). The final product had a radiochemical puritymore than 95%with a specific activity closely of
1000 Mbq/ml and the osmolality was around 200-300 mOsm/kg.
PET imaging system
Whole-body microPET/CT images were acquired with the Albira PET/CT Preclinical Imaging System (Bruker Biospin; Woodbridge,
CT, US). The PET subsystem comprises three rings of eight compact modules based on monolithic crystals coupled to multi-anode
photomultiplier tubes (MAPMTs), which form an octagon with an axial FOV of 40 mm/ring and a transaxial FOV of 80 mm in diameter.
The PET radial spatial resolution is 1.55mm (full width at half-maximum) and the absolute sensitivity of the system is 2% for a 350-650
keV energy window and a 5 ns timing window.
Image acquisition
Rats were anesthetized with a gaseous mixture of 2.5% isoflurane in oxygen in an anesthesia chamber before the injection of (7.4 ±
1.85) MBq of 18F-FDG on the tail vein. The anesthesia was interrupted immediately after the injection and the rats were placed back
on the cage and remained awake during the uptake period. The acquisition was performed 45 ± 10 min after the 18F-FDG injections.
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Again, animals were pre-anesthetized with 2.5% isoflurane in oxygen in an anesthesia chamber, approximately during two minutes,
and then transported to the scanner bed, where they were kept asleep under a concentration of 2% isoflurane in oxygen. Two bed
positions were acquired during 30 min for scanning the whole-body of the animal. Images were generated by using the Bruker Albira
Suite Software Version 5.0. Scatter and random coincidences were corrected by using the algorithms provided by the manufacturer.
Attenuation correction was not performed. Images were reconstructed by using the maximum likelihood expectation maximization
(MLEM) algorithm: 6 iterations were performed with an output pixel size of 0.4 3 0.4 3 0.4 mm3.
Image analysis and statistics
The brown fat area was delineated by using image tools implemented the AMIDE Software (http://amide.sourceforge.net/) to
generate a three-dimensional spherical volume of interest with radius of 6 mm and centered on the brown fat area. Thus, mean stan-
dardized uptake values (SUV) were calculated. The PET-CT analysis was performed in the Molecular Imaging Unit of the Department
of Nuclear Medicine of University of Santiago de Compostela.
Calorimetric system and nuclear magnetic resonance
Animals were analyzed for EE, RQ and LA using a calorimetric system (LabMaster; TSE Systems; Bad Homburg, Germany). Animals
were placed in a temperature-controlled (24C) box through which air was pumped. After calibrating the system with the reference
gases (20.9% O2, 0.05% CO2 and 79.05% N2), the metabolic rate was measured for 2-3 days, as previously shown (Imbernon et al.,
2013; Martı´nez deMorentin et al., 2014). EE, RQ (VCO2/VO2) and LAwere recorded every 30min. Animals were placed for adaptation
for 1 week before starting the measurements.
For the measurement of body composition, we used nuclear magnetic resonance (NMR) (Whole Body Composition Analyzer;
EchoMRI; Houston, TX). EchoMRI is a body composition analyzer for live subjects measuring body fat and lean masses with short
scan times to keep the comfort of the animals. Animals do not need to be anesthetized neither other special preparation before mea-
surement. They are placed in a holder of custom-defined size during the measurement (measuring time: 0.5-3.2 min). Two measure-
ments were done for animal, as previously shown (Imbernon et al., 2013; Martı´nez de Morentin et al., 2014).
BAT Temperature measurements
Skin temperature surrounding BATwas recordedwith an infrared camera (B335: Compact-Infrared-Thermal-Imaging-Camera; FLIR;
West Malling, Kent, UK) and analyzed with a specific software package (FLIR-Tools-Software, FLIR; West Malling, Kent, UK) as pre-
viously shown (Martı´nez deMorentin et al., 2014; Contreras et al., 2014). For each image, the area surrounding BATwas delimited and
the average temperature of the skin area was calculated as the average of 2 pictures/animal.
Sympathetic nerve activity recording
Multi-fiber recording of sympathetic nerve activity (SNA) was obtained from the nerve subserving BAT as previously described (Lo´pez
et al., 2010; Martı´nez de Morentin et al., 2014; Contreras et al., 2014). Animals were anesthetized using intraperitoneal ketamine
(91 mg/kg) and xylazine (9.1 mg/kg) and maintained anesthesia with a-chloralose (initial dose: 25 mg/kg, sustain dose: 50 mg/kg/h)
via a catheter inserted in the femoral vein. The trachea was cannulated, and each rat was allowed to breathe spontaneously oxy-
gen-enrichedair. Rectal temperaturewasmaintainedat 37.5Cusinga temperature-controlled surgical table anda lamp.Weobtained
multi-fiber recording of SNA from the nerve subserving BAT. Using a dissecting microscope, a nerve fiber innervating interscapular
BAT was identified, placed on the bipolar platinum-iridium electrode. Each electrode was attached to a high-impedance probe
(HIP-511, Grass Instruments,Warwick, RI, USA) and the nerve signal was amplified 105 timeswith aGrass P5 ACpre-amplifier (Grass
Instruments,Warwick, RI, USA). After amplification, the nerve signal was filtered at a 100- and 1000-Hz cutoff with a nerve traffic anal-
ysis system (Model 706C, University of Iowa Bioengineering; Iowa City, IA, USA). The nerve signal was then routed to an oscilloscope
(Model 54501A, Hewlett-Packard; Palo Alto, CA, USA) for monitoring the quality of the sympathetic nerve recording and to a resetting
voltage integrator (Model B600c, University of Iowa Bioengineering, Iowa City, IA, USA). BAT SNA measurements were made every
15min during 6 hr for the T3 ICV treatment in rats. For the analysis of SNA in SF1-Cre AMPKa1flox/floxmice and their control littermates,
basal measurements were performed during 30 min. To ensure that electrical noise was excluded in the assessment of sympathetic
outflow, we corrected each SNA recording for post-mortem background activity.
Sample processing
Rats and mice were killed by cervical dislocation. From each animal, either the whole brain (for IHC), the hypothalamus, or the MBH,
VMH and ARC (dissected from thewhole hypothalamus), as well as the liver and the BAT (for western blot or RT-PCR) were harvested
and immediately homogenized on ice to preserve phosphorylated protein levels. Sampleswere stored at80Cuntil further process-
ing. Dissection of the VMH and ARC was performed by micropunches under the microscope (Lo´pez et al., 2010; Martı´nez de Mor-
entin et al., 2014; Contreras et al., 2014; Martı´nez-Sa´nchez et al., 2017). The specificity of the VMH dissections was confirmed by
analyzing the mRNA of steroidogenic factor 1 (SF1) and proopiomelanocortin (POMC) (data not shown).
Quantification of lipids
Tissues (30mg) were homogenizedwith 10 volumes of ice-cold phosphate buffered saline (PBS) in a Potter homogenizer (20 strokes).
Fatty acids were measured in homogenates using a kit (Wako Chemicals; Richmond, VA; US) and TG were quantified as described
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(Martı´nez-Un˜a et al., 2015). Briefly, lipids were extracted from 1.5 mg of protein from homogenates (Folch et al., 1957) and TG were
measured in the lipid extract with a kit (A. Menarini Diagnostics; Ripolli, Italy).
De novo lipogenesis in tissues
De novo lipogenesis was performed as previously described (Nassir et al., 2013) with slight modifications (Aspichueta et al., 2005).
Freshly isolated tissue slices (40 mg) were incubated in high glucose Dulbecco’s Modified Eagle Medium (DMEM) with insulin
(150 nM) and 20 mM acetate with [3H] acetic acid 20 mCi/ml for 4 hr. Tissue slices were washed five times in cold PBS, homogenated
in PBS and lipids were extracted as previously described (Folch et al., 1957). Then, lipids were separated by thin-layer chromatog-
raphy (TLC) (Ruiz and Ochoa, 1997), the band corresponding to TG was scraped and the radioactivity was measured in a scintillation
counter.
Fatty acid oxidation in tissues
Beta oxidation was assessed as described before (Hirschey et al., 2010; Gao et al., 2015). Fresh liver and BAT pieces were homo-
genated in a Potter homogenizer (5 strokes) in cold buffer (25 mM Tris-HCl, 500 nM sucrose, 1 mM EDTA-Na2 pH 7,4) and sonicated
for 10 s. Then, the homogenates were centrifuged at 500 xg for 10min at 4C. Approximately 500 mg of protein from the homogenates
supernatant was used for the assay in a volume of 200 ml. The reaction started by adding 400 ml of assaymixture containing 200 mMof
0.5 mCi/ml [1-14C] palmitic acid to the samples which were incubated for 1 hr at 37C in eppendorf tubes with aWhatman paper circle
in the cap. The reaction was stopped by adding 300 ml of 3 M perchloric acid and 1 M NaOH was added to impregnate the Whatman
cap. After 2 hr the Whatman caps were retired and the radioactivity associated was measured in a scintillation counter. The eppen-
dorf tubes were centrifugated at 21.000 xg 10 min at 4C. Four hundred ml from the supernatant were collected and the radioactivity
was counted in a scintillation counter. The supernatant contained the acid soluble metabolites (ASM) and the Whatman caps
captured the released CO2.
Measurements of oxygen consumption rate
The respiration of primary hepatocytes, intact BAT, and liver and BAT mitochondria was measured at 37C by high-resolution respi-
rometry with the Seahorse Bioscience XF24-3 Extracellular Flux Analyzer. For the measurement of the oxygen consumption rate
(OCR), as the rate change of dissolved O2, primary mouse hepatocytes were seeded respectively in a collagen I coated XF24 cell
culture microplate (Seahorse Bioscience; Agilent Technologies; Santa Clara, CA, US), at 2.0 3 104 cells/well. After 2 hr of plating,
growth medium was removed and replaced with 500 mL of assay medium pre-warmed to 37C, composed of DMEM without bicar-
bonate containing 1 mM sodium pyruvate, 2 mM L-glutamine, and cultured at 37C in room air. Basal measurements of OCR were
performed after equilibration in assay medium for 1h. The normalized data were expressed as pmol of O2/minute/mg protein for pri-
mary hepatocytes. OCR in BATwasmeasured short after sacrifice and small pieces of tissuewere seeded in Seahorse plates with the
above-mentioned assay medium and trapped using islet capture microplates provided by the company. At the end of experiment,
OCR values were normalized to protein tissue content. For mitochondrial respiration experiments, liver and BAT mitochondria were
isolated by amethod similar to Schnaitman andGreenawalt (Schnaitman andGreenawalt, 1968) and basal respirationmeasurements
were made in the presence of succinate and rotenone. The normalized data were expressed as pmol of O2/minute/mg protein for
isolated mitochondria.
Electron microscopy and stereological analysis
For electron microscopy experiments, small pieces of BAT samples (1 mm3) were fixed with 1% glutaraldehyde/2% paraformalde-
hyde in 0.1 M cacodylate buffer for 6-8 hr at 4C and postfixed with 1% OsO4 in 0.1 M cacodylate buffer (2 hr at 4C). Samples were
then dehydrated and embedded in EMbed 812 resin (Electron Microscopy Sciences, Hatfield, PA, USA) for 48 hr at 65C. After
trimming, resin blocks were sectioned in an Ultracut Reicher Ultramicrotome to obtain ultrathin (40-60 nm) sections, which were
contrasted with 2% uranyl acetate for 7 min, and 3% lead citrate for 6 min at 37C and in the absence of CO2. Samples were visu-
alized in a JEOL JEM-1400 Transmission Electron Microscope (Jeol; Peabody, MA, USA) by a blinded investigator. Between 5 and
10 high resolution images/animal (n = 4) and experimental condition were acquired and processed using ImageJ 1.44 software (NIH;
Bethesda, MD, USA). Briefly, mitochondrial and lipid droplet ultrastructure and stereology were assessed from low-magnification
micrographs (4,000 X) containing whole brown adipocytes, from which planimetric parameters (lipid droplet and mitochondria num-
ber/area unit, area, and circularity coefficient) were calculated. For planimetric measurements more than 2,000 lipid droplets and
10,000 mitochondria/experimental group were scored. Lipid droplet and mitochondria size frequency distributions were calculated
using the total number of organelles visualized/experimental condition.
Blood biochemistry
The blood of the animals was collected in specific tubes (BD Vacutainer; Plymouth, UK) and centrifuged during 15 min at 2000 xg to
separate the serum. Levels of TSH, T3 and T4 were measured using rat ELISA kits (Crystal Chem; Downers Grove IL, USA) (Lo´pez
et al., 2010; Varela et al., 2012). Serum levels of FGF21 were measured using a rat kit (Biovendor; Karasek, Czech Republic). Ketone
bodies were quantified using a commercially available kit fromWakoChemicals GmbH (Richmond, VA, USA). All measurements were
done following the manufacturer’s instructions specifically.
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Fatty acid analysis
Total lipids were extracted from 15 mg of frozen liver tissue using a modified Folch extraction method. Deuterated tridecanoic acid
(C13D25O2H, Cambridge Isotopes; Andover, MA, USA) was used as internal standard. Total lipids were saponified and derivatized
into fatty acid methyl esters using boron trifluoride (Morrison and Smith, 1964). Samples were resuspended in hexane and analyzed
on a Thermo Finnigan Focus GC coupled to a FID detector. A Thermo Scientific TR-FAME column (length: 30 m, inter diameter:
0.25 mm, film size: 0.25 mm; Thermo Scientific; Surrey, UK) was used with helium as carrier gas at 1.9 ml/min. Inlet temperature
was 230C and detector temperature was 250C. Temperature program was as follows: 100C for 2 min, 25C/min for 2 min,
2.5C/min for 4.8 min, hold for 3.8 min, 4.5C/min for 2.4 min, hold for 5 min, 5C/min for 7.4 min, 40C/min for 0.5 min and hold
for 0.5 min. Chromatograms were analyzed and quantified using Xcalibur 2.0 (Thermo Scientific; Surrey, UK). Identification of
FAME peaks wasmade by comparing retention times against external standards (Restek 35077 Food industry FAMEmix; Bellefonte,
PA, USA; and Supelco 46904 Vaccenic Methyl ester; Sigma-Aldrich, St Louis, MO, USA). Data were normalized to internal standard
and followed by adjustment for tissue weight. Results are expressed as molar percentages normalized to control animals.
TLC separation of lipids for 14C experiments
Extracted total lipids were resuspended in chloroform and spotted onto TLC plates (Plastic Backed SilicaMatrix, Merck; Hoddesdon,
UK) for separation of TG and FA. Chromatography was performed using toluene:chloroform:methanol (85:15:5) as the migrating sol-
vent. Lipid bands were visualized using a primuline solution and scraped into scintillation vials for 14C quantification once plates
had dried.
Calculation of 14C specific activity
Tissue/serum lysates or lipid extracts were resuspended in Beta-Fluor Scintillans (National Diagnostics; Atlanta; USA) and
decays/min measured using a scintillation counter (LabLogic 300SL, LabLogic; Broomhill, UK).
Ceramide quantification
Ceramides were extracted and analyzed using liquid chromatography-mass spectrometer consisted of a Waters Acquity UPLC
System connected to a Waters LCT Premier Orthogonal Accelerated Time of Flight Mass Spectrometer (Waters; Millford, MA,
USA), operated in positive electrospray ionization mode. Full scan spectra from 50 to 1500 Da were acquired and individual spectra
were summed to produce data points each 0.2 s. Mass accuracy and reproducibility weremaintained by using an independent refer-
ence spray by the LockSpray interference. The analytical columnwas a 100mmL 2.1mm i.d., 1.7mmC8Acquity UPLCBEH (Waters;
Millford, MA, USA). The twomobile phases were phase A:methanol; phase B: water, both contained 0.2% formic acid (v/v) and 2mM
ammonium formate. A linear gradient was programmed (0.0 min: 20% B; 3 min: 10% B; 6 min: 10% B; 15min: 1% B; 18 min: 1% B;
20min: 20%B; 22min: 20%B). The flow rate was 0.3 mL/min. The column was held at 30C. Quantification was carried out using the
extracted ion chromatogram of each compound, using 50mDawindows. The linear dynamic rangewas determined by injecting stan-
dard mixtures. Positive identification of compounds was based on the accurate mass measurement with an error < 5 ppm and its LC
retention time, compared to that of a standard (±2%). Concentrations were measured by multiple reaction monitoring experiments
using N-lauroyl-D-erythro-sphingosine (C12-ceramide) and N-Heptadecanoyl-D-erytro-Sphingosine (C17-ceramide) as internal
standards and using as patrons N-Palmitoyl-D-erytro-sphingosine (C16-ceramide), N-Stearoyl-D-erytro-sphingosine (C18-
ceramide), N-lignoceroyl-D-erythro-sphingosine (C24-ceramide) and N-nervonoyl-D-erythro-sphingosine (C24:1-ceramide) (Avanti
Polar Lipids; Alabaster, AL, USA). The ceramide analyses were performed in the Research Unit on Bioactive Molecules (RUBAM) of
the Institut de Quı´mica Avanc¸ada de Catalunya (IQAC-CSIC).
Lipidomics
Sample preparation
Hypothalami were dissectedweighed and 20 mL of an internal standardmixture and 100 mL of NaCl (0.9%) were added to the sample.
Lipids were extracted from the samples with 400 mL of chloroform:methanol (2:1) solvent and the tissue was homogenized. After vor-
texing for 2 min and incubating for 1 hr at room temperature, the lower layer (approximately 100 mL) was separated by centrifugation
at 10,000 rpm for 3 min at room temperature. Ten mL of labeled standard mixture was added to the lipid extract. The internal standard
mixture contained the following lipid compounds with heptadecanoic acid (C17:0) as the esterified fatty acid: ceramide (d18:1/17:0)
(91.6 mg/mL; Avanti Polar Lipids; Alabaster, AL, USA), GPCholine (17:0/17:0) (9.9 mg/mL; Avanti Polar Lipids; Alabaster, AL, USA),
GPEthanolamine (17:0/17:0) (89.5 mg/mL; Avanti Polar Lipids; Alabaster, AL, USA) and TG (17:0/17:0/17:0) (103.6 mg/mL; Larodan
Fine Chemicals; Limhamn, Sweden). The labeled standard mixture consisted of GPCholine (16:0/0:0-D3) (92.8 mg/mL; Larodan
Fine Chemicals, Limhamn, Sweden), GPCholine (16:0/16:0-D6) (116.8 mg/mL; Larodan Fine Chemicals, Limhamn, Sweden) and
TG (16:0/16:0/16:0-13C3) (99.6 mg/mL; Larodan Fine Chemicals, Limhamn, Sweden).
Lipidomic analysis
Lipid extracts were analyzed at VTT Technical Research Centre of Finland (Espoo, Finland) on a Q-ToF Premier mass spectrometer
(Waters; Milford, MA, USA) combined with an Acquity Ultra Performance Liquid chromatography (UPLC/MS; Chicago, IL, USA). The
columnwas anAcquity UPLCBEHC18 10x50mmwith 1.7 mmparticles and kept at 50C. The binary solvent systemA includedwater
(1% 1M NH4Ac, 0.1% HCOOH) and solvent system B included LC/MS grade acetonitrile/isopropanol (5:2, 1% 1M NH4Ac, 0.1%
HCOOH) (Rathburn; Walkerburn, UK). The gradient started from 65% A/ 35% B, reached 100% B in 6 min and remained there for
Cell Metabolism 26, 212–229.e1–e12, July 5, 2017 e10
the next 7 min. The total run time including a 5 min re-equilibration step was 18 min. The flow rate was 0.2 mL/min and injection vol-
ume 1 mL. The temperature of the sample organizer was set at 10C. The lipid profiling was carried out using positive ion mode. The
data was collected at mass range of m/z 300-2000with scan duration of 0.2 s. The source temperature was set at 120C and nitrogen
was used as desolvation gas (800 L/h) at 250C. The voltages of the sampling cone and capillary were 39 V and 3.2 KV, respectively.
Reserpine (50 mg/L) was used as the lock spray reference compound (5 mL/min; 10 s scan frequency).
Lipidomic data processing and analysis
The obtained data was converted into netCDF file format using Dbridge Software from MASSLYNX (Waters; Milford, MA, USA). The
converted data was processed using MZmine Software version 0.60 . Lipids were identified based on their retention time (RT) and
mass to charge ratio (MZ) using our in-house built lipid database. All the identified lipids were quantified by normalizing with corre-
sponding internal standards. All monoacyl lipids except cholesterol esters, such as monoacylglycerols and monoacyl-glycerophos-
pholipids were normalized with GPCho (17:0/0:0). All diacyl lipids, except ethanolamine phospholipids, were normalized with GPCho
(17:0/17:0). The diacyl ethanolamine phospholipids were normalized with GPEth (17:0/17:0) and the triacylglycerols and cholesterol
esters normalized with TG (17:0/17:0/17:0).
Immunohistochemistry
Enzymatic immunohistochemistry was performed as previously described (Lo´pez et al., 2010; Varela et al., 2012; Martı´nez de
Morentin et al., 2014), using a rabbit anti-c-FOS (Santa Cruz Biotechnology, CA, USA). After perfusion of the animals through the
ascending aorta with 150 mL 0.9% NaCl, followed by 500 mL of 4% formaldehyde in 100 mM phosphate buffer (PB), pH 7.4, under
deep anesthesia with ketamine-xylazine. The tissues were fixed in 10% buffered formaldehyde and subsequently treated for histo-
logical study by dehydration (increasing alcohol concentrations), mounting in xylene and immersion in paraffin. The paraffin blocks
were sliced into 3 mm sections that were processed, deparaffinized in xylene, rehydrated and rinsed in distilled water, then stained
with the specific primary antibody and incubated overnight, washed and incubated with the secondary antibody (Dako EnVision sys-
tem, peroxidase; Glostrup, Denmark). c-FOS positive cells were counted by using ImageJ-1.33 (NIH; Bethesda, MD, USA). Seven-11
bilateral image sections per animals were analyzed. Direct detection of GFP fluorescence was performed after perfusion of the an-
imals; on 40 mm sections. Images were taken with a fluorescence microscope Olympus IX51 (Olympus Corporation; Tokyo, Japan).
Hepatic lipid content was analyzed by Red Oil O staining as previously shown (Imbernon et al., 2013; Contreras et al., 2014; Mar-
tı´nez-Sa´nchez et al., 2017). Hepatic frozen sections were cut (8 mm) and fixed in 10% buffered formaldehyde. Sections were stained
in filtered Oil Red O (Sigma-Aldrich; St. Louis, MO, USA), washed in distilled water, counterstained with Harris hematoxylin (Bio-
Optica; Milan, Italy) and washed in distilled water again. Sections were mounted in aqueous mounting medium (Bio-Optica; Milan,
Italy). Images were taken with a digital camera Olympus XC50 (Olympus Corporation; Tokyo, Japan) at 20x (for rats) and 40x (for
mice). Digital images for liver were quantified with ImageJ-1.33 (NIH; Bethesda, MD, USA).
In situ hybridization
Coronal brain sections (16 mm) were cut on a cryostat and immediately stored at 80C until hybridization. In situ hybridization was
performed as previously described (Lo´pez et al., 2010; Martı´nez deMorentin et al., 2014). Sections were probed with a specific oligo-
nucleotide for TRH (Trh; GenBank: NM_013046; 50- ATA CCAGTT AGGGTG AAG ATC AAA GCC AGAGCC AGC AGC AAC CAA–3’)
or AMPKa1 (Prkaa1; GenBank: NM_001013367; 50- GCTCTCCTCCAGAGACAT ATTCCA TCACCA TGA-30). These probes were 30
end labeled with 35S-adATP (Perkin Elmer, Waltham, MA, USA) using terminal deoxynucleotidil transferase (New England Biolabs;
Ipswich, MA). The specificity of the probes was confirmed by incubating the sections with an excess of the unlabeled probes.
The frozen sections were fixed with 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4) at room temperature for 30 min.
They were then dehydrated using 70, 80, 90, 95%, and absolute ethanol (5 min each). The hybridization was carried out overnight
at 37C in amoist chamber. Hybridization solution contained 0.5x106 cpm (for both TRH and AMPKa1) per slide of the labeled probe,
4X saline-sodium citrate buffer (SSC), 50%deionized formamide, 1XDenhardt’s solution, 10%dextran sulfate and 10 mg/ml sheared,
single-stranded salmon sperm DNA (all of them, Sigma-Aldrich; St. Louis, MO, USA). Afterward, the hybridization sections were
sequentially washed in 1X SSC at room temperature, four times in 1X SSC at 42C (30 min per wash), one time in 1X SSC at
room temperature (1 h), and then rinsed in water and ethanol. Finally, the sections were air-dried and exposed to Hyperfilm
b-Max (KODAK; Rochester, NY, USA) at room temperature for 7 days for TRH and 14 days for AMPKa1. The slides from all exper-
imental groups were exposed to the same autoradiographic film and then they were developed in developer/replenisher (Developer
G150, AGFA HealthCare: Mortsel, Belgium) and fixator (Manual Fixing G354; AGFA HealthCare: Mortsel, Belgium). Sections were
scanned and the hybridization signal was quantified by densitometry using ImageJ-1.33 software (NIH; Bethesda, MD, USA). The
optical density of the hybridization signal was determined and subsequently corrected by the optical density of its adjacent back-
ground value. A rectangle, with the same dimensions in each case, was drawn enclosing the hybridization signal over each nucleus
and over adjacent brain areas of each section (background) (Lo´pez et al., 2010; Martı´nez de Morentin et al., 2014). Sixteen-20 sec-
tions for each animal (4-5 slides with 4 sections/slide) were used. Themean of these 16-20 values was used as densitometry value for
each animal.
Real-time quantitative RT-PCR
Real-time PCR (TaqMan; Applied Biosystems; Foster City, CA, USA) was performed using specific primers and probes (Table S1) as
previously described (Lo´pez et al., 2010; Martı´nez deMorentin et al., 2014; Martı´nez-Sa´nchez et al., 2017). Total RNAwas isolated by
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using Trizol Reagent (Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s protocol (RNA was precipitated with chloro-
form and isopropanol, washed with 75% ethanol, and finally dissolved in RNase-free water). cDNA synthesis was performed with
M-MLV enzyme (Invitrogen; Carlsbad, CA, USA) following the supplier’s protocol. All reactions were carried out using the following
cycling parameters: 50C for 2 min, 95C for 10 min followed by 40 cycles of 95C for 15 s, 60C for 1 min. Values were expressed in
relation to hypoxanthine-guanine phosphoribosyl-transferase (Hprt) levels.
Western blotting
Protein lysates from hypothalamus (total, MBHor VMH), liver, muscle,WAT andBATwere homogenized in lysis buffer (consisting of a
mix of 0.05 M Tris-HCl, 0.01 M EGTA, 0.001 M EDTA, 0.016 M Triton X-100, 0.001 M sodium orthovanadate, 0.05 M sodium fluoride,
0.01 M sodium pyrophosphate and 0.25 M sucrose, made up with distilled water and adjusted to 7.5 pH; all of them from Sigma-
Aldrich; St. Louis, MO, USA) and freshly added protease inhibitor cocktail tablets (Roche Diagnostics; Indianapolis, IN, USA). The
protein concentration was determined by the Bradford Method (Protein assay dye concentrate, Bio-Rad Laboratories; Hercules,
CA, USA), and the total protein content of the tissues was calculated. The protein lysates were subjected to SDS-PAGE, electrotrans-
ferred to polyvinylidene difluoridemembranes (PVDF; Millipore; Billerica, MA, USA) with a semidry blotter and probed with antibodies
against ACC, AMPKa1, AMPKa2 (Millipore; Billerica, MA, USA), GRP78, IREa, pACCa (Ser79), pAMPKa (Thr172), p-c-Jun (Ser63),
pHSL (Ser660), PERK, pJNK (Thr183/Tyr185), pSTAT3 (Ser727) (Cell Signaling; Danvers; MA, USA); FAS (BD; Franklin Lakes, NJ,
USA); ATF6a, CHOP, JNK1/3, NFkB p65, peIF2a (Ser52), p-IKKa/b, pPERK (Thr981), PKCd (Santa Cruz; Santa Cruz, CA,USC);
HSL, pIREa (Ser724), PKCε, SPTLC1, SPTLC2, UCP1, UCP3 (Abcam; Cambridge, UK); a-tubulin or b-actin (Sigma-Aldrich; St. Louis,
MO, USA) as described (Lo´pez et al., 2010; Varela et al., 2012; Martı´nez de Morentin et al., 2014; Contreras et al., 2014; Martı´nez-
Sa´nchez et al., 2017). Each membrane was then incubated with the corresponding secondary antibody: anti-mouse, anti-rabbit or
anti-goat (all of them from DAKO; Glostrup, Denmark). The membranes were exposed to an X-ray film (Fujifilm; Tokyo, Japan) and
developed using developer (Developer G150; AGFA HealthCare: Mortsel, Belgium) and Fixator (Manual Fixing G354; AGFA Health-
Care: Mortsel, Belgium).
Autoradiographic films were scanned and the bands signal was quantified by densitometry using ImageJ-1.33 software (NIH;
Bethesda, MD, USA). Values were expressed in relation to b-actin (hypothalamus, liver and WAT) or a-tubulin (muscle and BAT).
In Figure 1A data are expressed as a percentage of vehicle ICV for each tissue. Representative images for all proteins are shown;
in the case of the loading controls a representative gel is displayed, although each protein was corrected by its own internal control
(b-actin or a-tubulin), as explained above. In all the Figures showing images of gels, all the bands for each picture come always from
the same gel, although they may be spliced for clarity. In the ACC westerns, the bands represent ACCa for liver, WAT and BAT and
ACCb for the muscle. In the pACC westerns, the upper band corresponds to pACCb and the lower band to pACCa.
QUANTIFICATION AND STATISTICAL ANALYSIS
ImageJ-1.33 software (NIH; Bethesda, MD, USA) was used to count c-FOS positive cells and to process electron microscopy, west-
ern blot analyses and in situ hybridization and liver histologic images (Lo´pez et al., 2010; Varela et al., 2012; Martı´nez de Morentin
et al., 2014; Contreras et al., 2014; Martı´nez-Sa´nchez et al., 2017). Statistical analysis was conducted using GraphPad Prism 6
Software (GraphPad Software; La Jolla, CA, USA). Data are expressed as mean ± SEM as percentage of stained area in the image
of the appropriate controls (euthyroid, vehicle-treated, GFP, sham-vehicle rats or WT mice). Error bars represent SEM. Statistical
significance was determined by t-Student (when two groups were compared) or ANOVA (when more than two groups were
compared) followed of post hoc two-tailed Bonferroni test. p < 0.05 was considered significant. The number of animals used in
each experimental setting and analysis are specified in each Figure Legend.
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